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The vaccinia virus expression system was developed into a scaleable recombinant 
protein production process in perfused mammalian cell culture.  Growth of anchorage 
dependent HeLa cells on microcarriers and the suspension adapted HeLa S3 cell line 
were studied in bioreactor cultures utilizing the ATF System or hollow fiber filter, 
respectively, for perfusion.  Recombinant vaccinia virus expressing enhanced green 
fluorescent protein (EGFP) as a model protein was used to study the effects of several 
process parameters on expression.  These included multiplicity of infection (MOI), 
volume during infection, serum concentration during infection, inducer concentration, 
timing of inducer addition relative to infection, and dissolved oxygen and temperature 
during the protein production phase.  Increases in protein yield were made as each of 
these parameters was studied.  The microcarrier based system reached 20 mg/l EGFP 
while the suspension based system achieved 27 mg/l under the conditions found 
  
through experiment.  A second virus containing the gene for gp120, an HIV envelope 
coat protein with complex post-translational modifications, was produced in 
microcarrier based bioreactor culture with HeLa cells.  The protein produced was 
purified and analyzed for post-translational modifications which found that half of the 
molecular weight was contributed through N-linked glycans.  The reactor culture 
produced 10.5 mg/l gp120 at 96 hours post infection with an ID50 of 3.1µg/ml.  A 
survey of expression, using both EGFP and gp120 expressing viruses, was conducted 
on several mammalian cell lines which may be more appropriate for commercial 
manufacturing processes.  Results varied, depending on the protein produced, with 
HeLa cells producing the most EGFP and BS-C-1 the most gp120.  293 cells 
performed fairly well in both cases and their use in other manufacturing processes 
and ability to grow in serum-free suspension culture lead to a recommendation that 
they be considered for further process development.  These studies have provided 
insight into the vaccinia virus expression system as a potentially large-scale 
production method for complex human proteins.  Further optimization of the process 
could continue to increase the yields and potentially bring this viral process into the 
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CHAPTER 1:  Introduction and Background 
1.1  Recombinant Protein Production 
Recombinant protein production is a method for generating large quantities of 
proteins which cannot be obtained from natural sources, especially proteins used as 
human therapeutics.  Generation of these proteins is accomplished by genetically 
engineering a cell line or vector to introduce the gene for the protein of interest into a 
cellular system and have those cells use their metabolic machinery to mass produce 
the protein.  The simplest method of production is fermentation with procaryotes such 
as Escherichia coli (E. coli).  It is attractive due to the short fermentation time and 
high yield but is limited to simple, unmodified proteins because prokaryotes do not 
posses the machinery to perform post-translational modifications.  Eukaryotic yeasts 
such as Pichia pastoris (P. pastoris) or Saccharomyces cerevisiae (S. cerevisiae) can 
be used to introduce some post-translational processing, but these often result in 
proteins with high mannose structures, different from those found on human proteins.  
Insect cells offer more post-translational processing, but proteins made in these cells 
are also not produced in the same manner as human proteins due to differences in N-
linked glycosylation and sialylation (Fang et al. 2000; Palomares et al. 2003; Percival 
et al. 1997), without significant metabolic engineering of the host cells (Ailor and 
Betenbaugh 1999; Ailor et al. 2000; Chang et al. 2003; Hollister et al. 2002; Hollister 
et al. 1998; Jarvis 2003; Jarvis et al. 1998; Palomares et al. 2003).  
Production of complex human proteins with the most appropriate post-




specifically, human cell lines. These processing modifications are often required for 
proper activity of the protein (Delorme et al. 1992; Eckhardt et al. 2002; Li et al. 
1993; Lifely et al. 1995; Nishikawa et al. 2000; Perrin et al. 1998). Transient DNA 
transfection can be used to obtain small quantities of proteins in a short period of time 
in mammalian cell culture, but for larger amounts and long-term production, stable 
transfection is required.  Development of a stable cell line can be long and laborious, 
increasing the cost of the product.  In order to overcome some of these limitations, 
viral vectors can be used with strong promoter elements to increase the yield of 
recombinant protein.  The viral based insect cell-baculovirus expression system has 
been shown to produce high levels of recombinant protein (Hu and Bentley 1999; 
Taticek et al. 2001; Taticek and Shuler 1997).  Although viral infection and protein 
expression is a transient process, it has several advantages.  Some viruses can shut-
down host functions and protein synthesis in order to devote more resources to viral 
processes (Broder and Earl 1999; Cacoullos and Bablanian 1993), including 
recombinant protein production.  Also, multiple cell lines can be tested for production 
characteristics without the long time required for cell line development.   
An investigation of the vaccinia virus expression system as a potentially large-
scale recombinant protein production method was chosen for this work because we 
wished to explore a viral expression method that could produce complex human 
proteins.  In order to increase the expression level of recombinant protein in this viral 
system, a vector utilizing the controllable T7 promoter was utilized and methods to 




1.2  Background 
1.2.1  Vaccinia Virus 
Vaccinia virus is an orthopoxvirus of the family Poxviridae.  It is closely 
related to the virus that causes Smallpox and has traditionally been used as the live 
viral vaccine against Smallpox.  Vaccinia has a wide host range that includes most 
mammalian species as well as humans (Broder and Earl 1999), allowing for infection 
of many mammalian cell lines.  Its use as a gene delivery vector in animal species  
(Brochier et al. 1991; Hanlon et al. 1998; Kieny et al. 1984; Wiktor et al. 1984) and 
humans (Cooney et al. 1991; Cooney et al. 1993; Gomella et al. 2001; Graham et al. 
1992; Hanke et al. 2002; McAneny et al. 1996; McClain et al. 2000; Zajac et al. 
2003) has been under investigation for several years.  The genetic material of vaccinia 
is comprised of a linear double stranded DNA molecule, approximately 200,000 bp 
(Moss 1996), with terminal hairpins and inverted repeats (Fenner et al. 1989).  
Researchers have found several regions within the genome that can accept 
interruptions of the sequence with recombinant DNA and still function effectively 
(Timiryasova et al. 1993).  These include the thymidine kinase (TK) gene, the 
hemaglutinin (HA) gene, and others.  Additionally, other researchers have shown that 
the genome can accept large genetic inserts, up to 25,000 bp of DNA without loss of 
function (Smith and Moss 1983).  
Vaccinia has the ability to shut down host cell protein synthesis after infection 
and, therefore, force the devotion of resources toward viral proteins and the 
recombinant protein associated with the virus (Broder and Earl 1999; Cacoullos and 




production machinery into the cell for transcription of viral and recombinant proteins 
within the cytoplasm (Moss 1996).  Because of this, the recombinant gene does not 
need to enter the nucleus to be transcribed, nor does the mRNA need to be transported 
out of the nucleus to be translated.  These transport phenomena may limit the size of 
protein which can be produced through transfection methods or other viral systems 
which do not have this feature (Moss 1996).  These unique features of vaccinia virus 
allow for post-translational modifications that follow the human processing pathway 
and for large recombinant gene inserts. 
Due to the infectivity of vaccinia, there are concerns for workers exposed to 
the virus.  Biosafety Level II precautions must be taken when working with 
unattenuated strains and workers should be vaccinated.  The Western Reserve (WR) 
strain used in this research is mostly cell associated and therefore large amounts of 
free virus are not present suspended in the culture medium (Blasco and Moss 1992), 
but this is still considered an infective strain and precautions must be taken.   
1.2.2  Vaccinia/lac Operon/T7 RNA polymerase/EMC leader (VOTE) 
Vaccinia virus is available with several different promoter elements that 
contain natural vaccinia promoters, synthetic promoters, common mammalian 
promoters such as CMV, or the T7 promoter system.  The VOTE vaccinia virus 
expression system was originally designed by Ward (Ward et al. 1995) and is based 
on the T7 promoter.  It is composed of two elements available from their laboratory.  
These include the WR strain of vaccinia modified with an insertion into the TK gene, 
vT7lacOI, and a plasmid, pVOTE, which contains several elements and a multiple 




modified from Ward (Ward et al. 1995), is shown in Figure 1-1.  The left portion is 
contained in the segment inserted into the TK region of vT7lacOI.  It contains the 
bacteriophage T7 RNA polymerase gene (T7 gene 1) under the control of a late 
vaccinia promoter.  Additionally, there is a lac O repressor binding site upstream of 
the polymerase gene that is used to reduce leaky expression by binding active 
repressor units and blocking transcription.  The lac repressor is produced within this 
same region from the lac I gene under a vaccinia early/late promoter.  The right side 
of Figure 1-1 contains the second element of this system, available in a plasmid, 
pVOTE.1 or pVOTE.2 with differing restriction endonuclease sites in the MCS.  It is 
flanked by left and right sequences of the HA gene to allow homologous 
recombination when transfected into a vaccinia infected cell.  The plasmid is used as 
a cloning vector where the DNA of the recombinant gene to be produced is inserted.  
It contains the E. coli gpt gene under the vaccinia early/late promoter that allows for 
selection of recombinant virus.  It also has a segment with the T7 promoter followed 
by a stem-loop/lacO (SLO) sequence that will be bound by active repressor molecules 
when in the uninduced state.  This is then followed by an encephalomyocarditis 
(EMC) leader to enhance translatability and stability, and the gene of interest is 
cloned immediately downstream of this segment.  Additionally, a triple terminator 
was included in order to stop transcription of open reading frame insertions.  
The recombinant gene of interest is cloned into the plasmid vector and then 
transfected into a cell line infected with vT7lacOI.  This results in recombinant virus 
due to homologous recombination with the HA flanking regions on the plasmid and 




Figure 1-1  VOTE Elements 
VOTE gene elements are shown in the uninduced (top) and induced (bottom) state.  
The left portion is contained within the TK gene of the vaccinia genome and the right 
portion is contained in the HA gene.  The gpt gene is controlled by the vaccinia 
early/late promoter to allow selection of the recombinant gene.  In the uninduced 
state, lac I is produced by an early/late promoter and produces repressor monomers 
that form active repressor tetramer units.  These bind to the lac O and SLO regions to 
stop transcription of the T7 gene 1 and the target gene, if leaky expression of T7 
polymerase should occur.  When induced, the repressor cannot form active units and 
the lac O and SLO are unbound.  This allows the late vaccinia promoter (PL) to 
produce T7 RNA polymerase that then binds to the T7 promoter.  The target gene is 
then transcribed from the SLO to the triple terminator (TT).  Translation of the target 
gene mRNA is enhanced by the EMC leader.  Figure reproduced with permission 
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selective conditions for the gpt gene by plaque isolation.  It is then amplified and 
purified to make a viral stock. 
1.2.3  HeLa Cells  
HeLa cells, originally derived from a human cervical adenocarcinoma (Gey et 
al. 1952; Jones et al. 1971), are available as an anchorage dependent (ATCC CL-2) or 
a suspension adapted cell line, HeLa S3 (ATCC CL-2.2).  These cells have been used 
extensively in research to produce small quantities of proteins with the vaccinia virus 
expression system.  Due to the base of available literature with these cells, and 
because they have proven successful in producing various proteins (Davis et al. 1996; 
Hu et al. 2000; Jun et al. 1996) our initial work focused on them as the host cell line.  
1.2.4  Cell Culture 
Methods of cell culture for recombinant protein production are available with 
various reactor configurations.  The choice of production system depends largely on 
the resources available and recombinant product characteristics, particularly the 
location of expression, intracellular or secreted (Bleckwenn and Shiloach 2004).  In 
small-scale work, tissue culture flasks are the primary method of cell growth for 
anchorage dependent cells whereas small shake or spinner flasks are the choice for 
suspension cells.  These methods are scaleable to a certain point, but eventually reach 
size limitations and must be modified for large-scale work.  Large-scale anchorage 
dependent methods include stacked plate systems, packed bed, fluidized bed, hollow 




usually performed in traditional stirred tank bioreactors (Sambanis and Hu 1993; 
Zhang et al. 1993).   
Microcarrier culture was chosen in this work as the method of growth for the 
anchorage dependent HeLa cells in a stirred tank bioreactor.  Microcarriers are small, 
usually spherical, beads made of a variety of materials onto which the anchorage 
dependent cells can attach.  The material of construction varies from glass, plastic, 
polymer, cross-linked dextran and others, with surfaces often coated with collagen, 
fibronectin, or positively charged to aid in cell attraction.  The carriers are designed to 
be suspended in liquid culture medium with mixing, but most will settle within a few 
minutes after stopping agitation.  By utilizing microcarriers, we can provide a solid 
support for the cells to attach and grow, but can suspend the cell covered carriers in 
liquid culture medium and treat the culture in much the same manner as cell 
suspension culture, with a few modifications.   
1.2.5  Bioreactor Technology and Perfusion (Microcarrier and Suspension) 
There are four main modes of operation of a bioreactor.  These are batch, 
where all nutrients for growth are present at the beginning of the run and no medium 
replenishment occurs; fed-batch, where the culture is run in batch mode until 
nutrients become limiting and then a feed solution is gradually added to the reactor; 
perfusion, where a cell separation device is used to retain all the cells in the reactor 
while medium is constantly removed and replaced; or continuous, where culture, 
including cells and medium, is constantly removed and fresh medium is added to the 
reactor (Bleckwenn and Shiloach 2004).  The mode which results in the highest cell 




addition of nutrients and removal of harmful waste products, unlike batch and fed-
batch.  Additionally, it is preferred over continuous culture because the slow growth 
rate of mammalian cells, relative to prokaryotes, makes continuous mode difficult to 
implement without causing washout (complete removal of all cells from the culture).  
Microcarrier and cell suspension based culture in a bioreactor can initially be run in 
batch mode.  Eventually, feeding, to supply nutrients for continued growth, and 
removal of waste products becomes necessary.  There are several systems available to 
aid in the perfusion of culture in a stirred tank bioreactor.  These include hollow fiber, 
spin filter, acoustic filter, and others.  These methods generally work well for single 
cell suspension culture (Woodside et al. 1998), but are often not suitable for work 
with microcarriers because they can clog and often require pumping the culture 
through tubing to the device, crushing and damaging the carriers and cells.  A system 
involving alternating tangential flow (ATF) external to the reactor was made 
available for our use from Refine Technologies (East Hanover, NJ).  It contains a 
screen module to retain the cell-covered microcarriers while removing medium from 
the culture.  It uses the alternating motion of a diaphragm to pull the culture into and 
push it out of the center of the unit through stainless steel tubing, avoiding pumping 
the culture through tubing.  By alternating the direction of flow of the culture, buildup 
of microcarriers on the screen module is mostly prevented, reducing clogging 
problems with this filter. This system was investigated as a means of perfusion in the 





1.2.6  Enhanced Green Fluorescent Protein 
Enhanced green fluorescent protein (EGFP) is a modified version of green 
fluorescent protein (GFP).  GFP was originally cloned from the jellyfish Aequorea 
victoria (Chalfie et al. 1994).  It is a naturally fluorescing protein that is non-toxic and 
requires no co-factors to produce fluorescence (Chalfie et al. 1994; Crameri et al. 
1996).  It is a fairly stable molecule (Chalfie et al. 1994) and has thus proven very 
useful in various biological studies as a visible tag.  EGFP differs slightly from the 
native protein in that it has been human codon usage optimized and the wavelength of 
excitation and emission are different (Clontech Laboratories 2000).  EGFP has a 
maximum excitation wavelength at 488 nm and an emission maximum at 509 nm.   
GFP variants have been used in a variety of organisms including E. coli, yeast, 
insect cells, insect larvae, and mammalian cell culture as model proteins to study 
production conditions (Albano et al. 1998; Cha et al. 1997; Kirsch et al. 2003; 
Meissner et al. 2001).  Previous researchers have also used GFP as fusion proteins 
with other genes of interest to track protein production (Albano et al. 1998; Cha et al. 
1999a; Cha et al. 1999b; Cha et al. 1999c; Cha et al. 2000; Crameri et al. 1996; 
DeLisa et al. 1999; Laukkanen et al. 1996; Li et al. 2000; Wu et al. 2000).  In several 
of these cases, fluorescence measurements have been shown to correlate well with the 
expression levels of the fusion protein. 
1.2.7  gp120 
gp120 is an HIV-1 envelope glycoprotein that has been considered a potential 
vaccine candidate against HIV infection (Cooney et al. 1991; Cooney et al. 1993; 




linked glycosylation sites that account for about half the molecular weight and are 
required for functionality (Li et al. 1993).  It was previously produced in a T7 
vaccinia virus system in a packed bed reactor (Hu et al. 2000).  The production level 
reached was 2-3 µg/106 cells.  The system required a co-infection of two viruses, one 
containing the T7 polymerase gene and the other containing gp120 under control of 
the T7 promoter.  It was shown to produce the correctly processed protein. 
1.2.8  Project Overview / Summary 
The initial research objectives for this project were as follows: 
1) Construct vaccinia virus strain with the gene for EGFP reporter protein  
2) Study the growth of anchorage dependent HeLa cells on various 
microcarriers to achieve high cell density growth 
3) Define the growth conditions for HeLa cells in bioreactor perfusion 
culture 
4) Investigate the infection and expression conditions with EGFP virus 
5) Construct vaccinia virus strain with the gene for gp120 protein 
6) Produce gp120 protein in bioreactor culture 
7) Analyze the post-translational processing and activity of recombinant 
gp120 
8) Develop and define a bioreactor production strategy using the recombinant 





Through the course of this research project, the following additional objectives were 
added: 
9) Investigate production strategies with the EGFP virus in the suspension 
adapted HeLa S3 cell line  
10) Define growth conditions for the HeLa S3 suspension cells in perfused 
bioreactor culture using a hollow fiber filtration device 
11)  Compare expression levels of EGFP and gp120 proteins with these 
vaccinia viruses in several cell lines with consideration for regulatory 
acceptability 
 
The work presented here is divided into several chapters which comprise 
papers submitted individually for publication.  Chapter 2 begins with the construction 
of a recombinant vaccinia virus, expressing EGFP as a reporter protein.  This virus 
was used to investigate several parameters related to infection for their effect on 
protein expression in tissue flask HeLa cell culture.  These were MOI, volume during 
infection, and serum concentration during infection.  MOI can have a significant 
effect on expression of recombinant viral protein.  A lowered volume during infection 
may alter the infection kinetics by increasing the chances of a virus particle 
encountering a cell.   Serum proteins may interfere with the binding of virus particles 
to the cell surface.  In addition to these parameters, evaluation of several commercial 
microcarriers was performed to find the most appropriate microcarrier for growth of 




This work was continued in Chapter 3 with an experiment to determine the 
best concentration of microcarriers for growth and infection of the cells.  More 
process parameters were studied in this work with the use of the EGFP reporter virus 
which included length of the infection phase and inducer concentration and timing of 
its addition relative to infection.  These two parameters have a direct effect on the 
expression of recombinant protein via control of the promoter.  Evaluation of MOI 
was performed for microcarrier culture with the conditions defined for growth of 
HeLa cells.  This was a re-evaluation of this parameter due to differences in the 
infection kinetics between the static tissue flask culture, studied previously, and the 
dynamic microcarrier based environment evaluated here.  The investigation of 
microcarrier based spinner flask culture was then extended to evaluate dissolved 
oxygen (DO) and temperature during the protein production phase for their effect on 
protein expression.  Sufficient oxygen supply may be necessary for optimum 
expression levels, but high levels could lead to decreased productivity through 
increases in protease activity or changes in the post-translational modifications of the 
protein, possibly affecting biological activity.  A reduced temperature may play a role 
in slowing the cytopathic effects from viral infection, potentially leading to a higher 
overall level of protein production.    
Chapter 4 begins with a description of the concerns for scale-up of this 
process.  The issues were each addressed, starting with a description of the bioreactor 
system and perfusion device used to obtain high cell density prior to infection.  A 
method of in-vessel trypsinization was studied to provide a scaleable alternative to 




obtained from previous chapters were used to define the production process, but DO 
and temperature were revaluated in the bioreactor because these parameters were 
better isolated in this controlled environment.  This chapter concludes with 
construction of a gp120 expressing virus and production of this protein in bioreactor 
culture.  Examination of the purified protein to determine the extent of post-
translational modifications and activity was also performed to verify the correct 
processing of a complex protein.   
The work was further expanded in Chapter 5 to the suspension adapted HeLa 
S3 cell line.  Here, several parameters were revisited with the EGFP reporter virus to 
determine the best levels at which to produce protein in spinner flask culture.  MOI 
and temperature during production were studied because differences in the way single 
cells are infected versus microcarrier attached cells and a slightly higher growth rate 
than the anchorage dependent HeLa cells warranted more study in this suspension 
system.  The results were then translated to the bioreactor scale where growth 
conditions were defined for perfusion culture using a hollow fiber filter.  Infection of 
the culture for production of EGFP was performed according to the results of the 
spinner flask experiments and previous work with the anchorage dependent cells.    
Chapter 6 then concludes the experimental results portion of this work with an 
evaluation of several mammalian cell lines for their expression levels of two proteins.  
EGFP was produced in the cytoplasm of the infected cells and gp120 was produced 
and secreted into the medium of infected cultures.  The expression levels and post-
translational modifications were compared between HeLa, BS-C-1, Vero, MRC-5, 




Chapter 7 summarizes the results found from these experiments and describes 





CHAPTER 2:  Exploring Vaccinia Virus as a Tool for Large 
Scale Recombinant Protein Expression1 
2.1  Summary 
A recombinant vaccinia virus was engineered to express enhanced green 
fluorescent protein (EGFP) under control of the T7 promoter using the VOTE 
expression system (Ward et al. 1995) in HeLa cells.  Infection of HeLa cells with this 
virus and induction with IPTG demonstrated the utility of this construct for easily 
measuring protein expression.  This construct was used to evaluate several production 
parameters, specifically, multiplicity of infection (MOI), volume during infection and 
serum concentration during the infection phase.  In static culture, increasing 
multiplicity of infection was found to increase expression of EGFP up to a plateau 
around MOI of 1.0. Expression was also shown to increase with decreasing volume 
during the infection phase.  Serum concentration during the infection phase was only 
marginally significant from 0 to 7.5%.  Cytodex® 3 microcarriers were found to have 
the best characteristics for HeLa cell growth.  These cells were grown and infected in 
microcarrier spinner flask culture and the maximum expression was 2.2 µg EGFP/106 
cells at the time of infection, demonstrating the ability of this system to successfully 
express recombinant proteins at larger scale. 
                                                 
1 Reproduced with permission from Bleckwenn NA, Bentley WE, Shiloach J. 2003. 
Exploring vaccinia virus as a tool for large-scale recombinant protein expression. 




2.2  Introduction 
 Production of proteins in recombinant systems is the preferred method for 
generating human therapeutics and several methods are available.  The use of bacteria 
such as Escherichia coli (E. coli) is currently the simplest method because of the 
short fermentation time and high yield.  But prokaryotic organisms are often unable to 
perform post-translational modifications that may be required for complex human 
protein activity.  To produce these proteins, eukaryotic cells such as yeast, insect, or 
mammalian cells may be utilized.  Although systems such as insect cells can produce 
large quantities of protein, they rarely make identical post-translational modifications 
to the proteins as are found in human cells (Fang et al. 2000; Percival et al. 1997) 
without significant metabolic engineering effort (Ailor and Betenbaugh 1999; Ailor et 
al. 1999; Ailor et al. 2000).  A human cell line is likely to achieve authentic 
processing of human proteins with minimal reengineering. 
An alternative mammalian production strategy for use as a bioreactor-scale 
production method is investigated in this work.  This method employs vaccinia virus 
to introduce the recombinant gene.  Vaccinia virus is an orthopoxvirus, of the family 
Poxviridae, which is related to the virus that causes Smallpox.  Traditionally, vaccinia 
has been used as the live viral vaccine agent against Smallpox infection until 
worldwide eradication of the disease in the 1970’s.  Vaccinia virus has several 
interesting characteristics.  First, the virus replicates in the cytoplasm of the infected 
cell and carries all of the necessary machinery for transcription into the cytoplasm of 
the infected cell (Moss 1996).  Therefore, the viral genes (and any recombinant genes 




transcribed.  Likewise, there is no need for transport of the mRNA transcripts out of 
the nucleus for translation.  These nuclear transport phenomena are thought to limit 
the size of a recombinant gene that can be produced by more traditional mammalian 
cell expression methods such as transfection (Moss 1996).  The second feature of 
interest for vaccinia is the wide host range.  This virus can infect most mammalian 
species including humans (Broder and Earl 1999).  Because of this, human cell 
culture can be used to produce recombinant human proteins that may be more 
authentically processed because the post-translational processing pathways of the host 
cell line are used.   The infectious nature of vaccinia virus should be taken into 
consideration, as vaccination of researchers and other employees who may be 
exposed is necessary.  In order to reduce this risk, less infective strains could be used 
such as the modified vaccinia virus Ankara (MVA), which was found to be less 
infective and pathogenic to humans due to its long passage history in chick embryo 
fibroblast cells (Carroll and Moss 1997; Sutter and Moss 1992).  These less infective 
strains could be engineered to produce recombinant proteins in much the same way as 
the more infective strains, but because most of the available complex expression 
systems were created with the more common infectious strains, the work described 
here was carried out using the Western Reserve (WR) strain of vaccinia for which 
Biosafety Level 2 procedures should be observed. 
 The production of recombinant protein using this vaccinia system was 
evaluated with a reporter virus strain carrying the gene for enhanced green fluorescent 
protein, EGFP.  This protein is a modified version of green fluorescent protein 




easily visualized within live cells using a fluorescent microscope and can also be 
quantified using a fluorescent spectrophotometer.  Many other researchers have used 
green fluorescent proteins as reporters to study production in various systems such as 
E. coli (Albano et al. 1998; Cha et al. 2000; DeLisa et al. 1999; Wu et al. 2000), 
yeast (Li et al. 2000), insect cells (Cha et al. 1999c; Laukkanen et al. 1996), insect 
larvae (Cha et al. 1999b; Cha et al. 1997), or mammalian cells (Crameri et al. 1996).  
This makes EGFP an ideal candidate for use as a reporter protein to study various 
production parameters in this system. 
 A key element of this production system is the use of the VOTE (vaccinia 
virus/lac operon/T7 RNA polymerase/EMC) vaccinia expression system (Ward et al. 
1995).  This system allows the use of a single virus that contains the elements 
necessary for T7 promoter controlled expression of the recombinant gene.  
Additionally, use of the lacO and a stem loop lacO (SLO) sequence provide tight 
control of expression through the addition of the inducing agent isopropyl-β-d-
thiogalactopyranoside (IPTG) (Ward et al. 1995).  The encephalomyocarditis (EMC) 
virus RNA leader has also been included to enhance stability and translatability of the 
recombinant transcripts (Ward et al. 1995).  This system has an advantage over 
previously studied vaccinia production systems in that it requires the use of only a 
single virus to achieve T7 promoter controlled expression.  Previous systems required 
dual infection wherein one virus contained the T7 RNA polymerase gene and another 
contained the recombinant gene under control of the T7 promoter (Barrett et al. 1989; 




of protein than the available native or synthetic promoters for vaccinia (Fuerst et al. 
1987; Fuerst et al. 1986). 
 To achieve high productivity, high cell density prior to virus infection is 
needed.  HeLa cells have been chosen because they are a human continuous cell line 
that can reach relatively high cell densities.  Although a suspension adapted cell line 
is available, the attachment dependent strain was chosen, due to the nature of the 
vaccinia strain used, which requires cell-to-cell contact for spread of the virus 
infection (Blasco and Moss 1992).  The attachment dependent nature of this line may 
enhance infection spread by offering more cell-to-cell contact.  Additionally, higher 
cell densities may be achieved in bioreactor culture with attachment dependent cells 
adhering to a solid surface, such as microcarriers, than with the suspension adapted 
cells.  
Several methods are available for growth of attachment dependent cells at a 
large-scale, all of which involve attachment to a solid substrate.   Reactor types such 
as cell factories, hollow fiber, packed bed, or microcarrier suspension culture can be 
used (Sambanis and Hu).  For this work, microcarrier culture has been chosen 
because one can use a traditional stirred tank vessel without investment in a new type 
of reactor, and cells can also be easily sampled from the culture for cell density 
measurements, which can be difficult with other reactor types.   
 In this work, we describe the implementation of the above components to 
study several production parameters, specifically multiplicity of infection (MOI, 
pfu/cell), volume during infection phase and serum concentration during the infection 




2.3  Materials and Methods 
2.3.1  Cell Type and Maintenance 
 HeLa cells (ATCC CCL-2) and BS-C-1 cells (ATCC CCL-26) were grown in 
tissue culture flasks and passaged every 3-4 days in Dulbecco’s modified Eagle’s 
medium with 4.5 g/l glucose (DMEM, Biofluids, Rockville, MD) and 10% fetal 
bovine serum (FBS, Biofluids).   
2.3.2  Cell Growth on Microcarriers 
 Cell growth on microcarriers in 150 ml spinner flasks (Corning, Acton, MA) 
was achieved by seeding HeLa cells with microcarriers prepared according to 
manufacturers’ directions.  During seeding, a reduced media volume was used and an 
intermittent stirring protocol was followed, where the agitation was run at 50 rpm for 
30 seconds every 20 minutes, for four hours.  At the end of the seeding stage, media 
was added to the final volume and the agitation was set to run at 50 rpm, 
continuously. 
2.3.3  Virus Construction and Stock Preparation 
 A reporter virus expressing the EGFP gene under control of the T7 promoter 
was constructed as follows (Figure 2-1).  The plasmid pEGFP-N1 was obtained from 
Clontech (Palo Alto, CA).  PCR primers were designed to allow amplification of the 
EGFP gene with Acc65 I and Not I restriction sites (5’- GAA TTC TGC AGT CGA 
CGG TAC C-3’ and 5’-GTC GCG GCC GCG TAC TTG TAC AGC TCG TCC-3’).  
This PCR product was then inserted into a pCR®4-TOPO® vector (Invitrogen, 




Figure 2-1  Plasmid Construction 
EGFP=enhanced green fluorescent protein gene, HIS=histidine tag gene, gpt=gpt 
selection gene, P(E/L)= vaccinia 7.5 early/late promoter, P(T7)= T7 promoter, 





performed on this plasmid to isolate the EGFP fragment, which was then inserted into 
the Acc65 I and Not I digested pSecTag2 A plasmid (Invitrogen).  Sequencing of the 
EGFP insert and 6×histidine tag (6×HIS) region confirmed the correct frame and 
gene sequence.  The resulting plasmid was denoted pNB006. 
PCR primers were designed to allow amplification of the EGFP plus 6×HIS 
from pNB006 with Nde I and EcoR I restriction sites (5’-CAT ATG GTG AGC AAG 
GGC GAG-3’ and 5’-GGG TTT GAA TTC AAT GAT GAT GAT G-3’).  The 
digested PCR product was then inserted into the pVOTE.2 vector (kindly supplied by 
B. Moss, NIAID, NIH) at the Nde I and EcoR I digestion sites.  The resulting vector 
plasmid, denoted pNB009, was checked by sequencing the region containing EGFP 
and 6×HIS.   
A recombinant vaccinia virus was then generated in a monolayer of HeLa 
cells in a T-25cm2 flask, by infecting cells with vT7lacOI (kindly provided by B. 
Moss, NIAID, NIH) at an MOI of 0.05 and then transfected with 5 µg pNB009 
plasmid DNA using Lipofectamine Plus (Invitrogen).  Recombinant vaccinia virus 
was isolated via gpt selective pressure and plaque purification was performed using 
infected BS-C-1 cells with agarose gel overlays (Moss and Earl 2000).  The gpt gene 
is contained on the pVOTE.2 plasmid near the recombinant gene for EGFP, and 
therefore, selection for the gpt gene also selects for the recombinant gene.   PCR 
analysis verified the presence of the recombinant virus and absence of vT7lacOI 
without the insert using the following primers 5’-CGG TGT CTG TAT GAT CTT 




Shors, NIAID, NIH) and 5’-GCT TTG TTA GCA GCC GGA TC-3’ with 5’-GGA 
AAG AGT CAA ATG GCT CTC C-3’.   
 Amplified recombinant virus was purified by ultra centrifugation (Beckman 
Coulter, Palo Alto, CA) at 32,000×g for 80 minutes on a 36% sucrose cushion.  The 
viral pellet was suspended in 10 mM Tris pH 9.0 and aliquots were frozen at -70°C.  
The recombinant virus is denoted vNB009. 
 Titer determination was performed by serially diluting trypsinized stock virus 
and infecting wells of BS-C-1 monolayers in 6-well plates, in duplicate (Moss and 
Earl 2000).  Dilutions from 10-6 to 10-11 were plated and the entire titer procedure was 
performed three times.  After three days of incubation at 37°C, 5% CO2, the cells 
were stained with a 37% formaldehyde, 5% ethanol solution containing crystal violet.  
Plaques were counted and the titer was determined by the average of the three sets.   
2.3.4  Analytical Methods 
2.3.4.1  Cell Counts and Viability Measurements 
 Viability assays were performed by 0.4% trypan blue (Sigma, St. Louis, MO) 
exclusion staining.  Cell counts were performed by counting cell suspension samples 
with a hemacytometer (Baxter Scientific, McGaw Park, IL).  Cells from microcarrier 
samples were prepared for these measurements by centrifuging a sample at 300×g for 
1 minute.  Aspiration of media and washing of the cell and microcarrier pellet with D-
PBS with calcium and magnesium (Invitrogen) followed.  The pellets were then 
resuspended in 1× trypsin-EDTA solution (Gibco, Cat. No. 25200072) and incubated 




DMEM+10% FBS was then added and the resulting cell suspension was used for 
counting and trypan blue exclusion staining. 
2.3.4.2  Glucose and Lactate Measurements 
 Glucose and lactate were measured from media samples with a YSI 2700 
Biochemistry Analyzer (Yellow Springs Instrument Company, Yellow Springs, OH). 
2.3.4.3  Fluorescence Measurements 
Fluorescence measurements for the MOI evaluation were performed in 96-
well black walled plates with cover glass bottoms (Nunc 164588, Naperville IL).  A 
SpectraMax Gemini fluorescence spectrophotometer (Molecular Devices, Sunnyvale, 
CA) was utilized in well-scan mode with 9 spatial readings per well and 6 overall 
readings per well which were averaged for each well and reported in relative 
fluorescence units (RFU).  The wavelength settings were an excitation of 485 nm and 
emission of 512 nm with an auto cutoff filter of 495 nm.   
Fluorescence measurements for all other experiments were made on samples 
and compared to standards of rEGFP (Clontech) in either lysis buffer (100 mM Tris 
pH 7.4 with 1× Complete™ protease inhibitor (Boehringer Mannheim GmbH, 
Germany) and 0.5% Triton X-100) or DMEM+10% FBS without phenol red.  The 
readings were converted to EGFP expression units of µg/106 cells at infection using 
the standard curves and cell count measurements.  A SpectraMax Gemini 
fluorescence spectrophotometer (Molecular Devices, Sunnyvale, CA) was utilized 
with wavelength settings at an excitation of 485 nm and emission of 512 nm with an 
auto cutoff filter of 495 nm.  Ninety-six-well black plates (Fisher Scientific, 




2.3.4.4  Virus Expression Verification 
Approximately one million HeLa cells in wells of a 6-well plate were infected 
at a MOI of 1.0 with vNB009 in 0.5 ml of DMEM without phenol red with 2.5% FBS 
and 1.0 mM IPTG for one hour with rocking of the plate at 15 minute intervals in a 
37°C, 5% CO2, humidified incubator.   At the end of the infection period, the media 
volume was increased to 2.5 ml (DMEM with 10% FBS and 1 mM IPTG) and 
incubated for 43 hours.  Additionally, one well was left uninfected and another was 
infected with the recombinant virus, but did not contain the inducing agent IPTG.  
Visualization of the cells was performed with a fluorescence microscope (DM IRB, 
Leica, Wetzlar, Germany) equipped with a FITC filter (Chroma, Brattleboro, VT).  
The images were recorded using digital photography (Kodak MDS 290 system, 
Fisher Scientific) at 200× magnification. 
2.3.4.5  96-well Multiplicity of Infection Evaluation 
Confluent HeLa cells were harvested from T-162cm2 flasks and counted.  The 
cells were divided into 0.5 ml aliquots with 4.0x106 cells/tube and incubated in 
serum-free DMEM at 37°C with the appropriate amount of vNB009 virus for 
infections at MOI 0.0, 0.01, 0.025, 0.05, 0.075, 0.10, 0.25, 0.50, 0.75, 1.0, 2.0, and 
5.0.  The incubation was performed in the presence of 1.0 mM IPTG for one hour 
with gentle agitation every 15 minutes.  At the end of the incubation, 3.5 ml 
DMEM+10% FBS with 1.0 mM IPTG was added and 1x105 cells were seeded into 
eight wells per MOI in four 96-well black walled plates with cover glass bottoms 
(Nunc 164588, Naperville IL), which were incubated at 37°C, 5% CO2 in a 




and fluorescence measurements made directly on the intact cells and media in the 
plate.  
2.3.4.6  6-well Parameter Evaluations 
 HeLa cells were harvested from confluent T-162cm2 flasks and seeded into 6-
well tissue culture plates at a density of 1.25x105 cells per well in 2 ml of 
DMEM+10% FBS without phenol red.  They were grown at 37°C, 5% CO2 in a 
humidified incubator for two days.  Cells were infected with vNB009 recombinant 
virus (MOI of 0.5, 1.0, 1.5, 2.0, 3.0, or 4.0) prepared in DMEM with appropriate 
amounts of FBS (0, 2.5, 5.0, or 7.5%).  Each well was infected with an appropriate 
volume (0.5 or 1.5 ml) for one hour with rocking of the plates at 15 minute intervals 
to prevent drying of the cells.   Entire wells were sacrificed for each sample where the 
cells were scraped and collected into a tube and pelleted by centrifugation (2,500×g, 5 
minutes).  Supernatant was removed and the pellet was frozen at -70°C.   
 The pellets were later analyzed for fluorescence by thawing to room 
temperature and resuspending in 250 µl lysis buffer.  The samples were incubated at 
37°C for 15 minutes with rigorous vortexing twice and then centrifuged (15,000×g, 5 
minutes) to pellet debris.  One hundred microliter samples of the supernatant were 
transferred to 96-well black plates for fluorescence measurements.   
2.3.4.7  Spinner Flask Infections 
 Cells were grown to confluency in T-162cm2 tissue culture flasks and counted 
after harvesting with cell dissociation solution.   Cytodex® 3 microcarriers were 
prepared according to manufacturer’s instructions and 0.2 g were placed in 125 ml 




HeLa cells were then seeded into the flasks by adding 10 ml of 1x106 cells/ml.  The 
flasks were placed in an incubator at 37°C, 5% CO2, in humidified conditions with 
stirring at 50 rpm for 30 seconds every 20 minutes for four hours.  The volume was 
then adjusted to 100 ml with DMEM+10% FBS without phenol red, leaving 1x105 
cell/ml and 2 g/l Cytodex® 3 in each flask.  Flasks were then incubated at 37°C, 5% 
CO2, in humidified conditions with stirring at 50 rpm.  Samples were taken daily for 
cell count, viability, glucose and lactate.  Feeding was performed, as deemed 
necessary by glucose and lactate measurements, by removing the flasks from the 
agitation source and allowing the microcarriers with cells to settle.  A portion of the 
media was then removed and replaced with fresh media.     
Cells were infected at day five when the cell density was approximately 1 to 
1.5 x106 cells/ml.   Infection was then carried out in a reduced volume of 50 ml, 
which approximates the cell to media volume ratio used for infection in 6-well plates 
of 0.5 ml/well.  The infection was done in serum-free media with 1 mM IPTG at 50 
rpm for one hour.  The volume was then increased to 100 ml with media and serum 
was added to a final 10% FBS.  Samples were taken at several times where cells on 
microcarriers were centrifuged (300×g), supernatant removed to a second tube and 
both were frozen at -70°C.  Cell count and viability measurements were made as 
previously described around 24 and 48 hours post infection.   
Fluorescence measurements were made on both media and pellet samples.  
Pellets were resuspended in 250 µl lysis buffer.  The suspension was then incubated 
at 37°C for 15 minutes with vigorous vortexing twice.  The debris was pelleted by 




measurements.   Standards of rEGFP were prepared in both media and the lysis 
solution used above.  Media and lysed pellet samples of 100 µl were transferred to 
96-well black plates along with both sets of standards.  Measurements of the EGFP 
fluorescence were made as described previously. 
2.4  Results and Discussion 
2.4.1  EGFP Expression  
 Construction of a recombinant vaccinia virus encoding for the production of 
EGFP was performed as described in the Materials and Methods section.  In brief, the 
EGFP gene was amplified from pEGFP-N1 (Clontech) and combined with the 
histidine tag region of pSecTag2.A (Invitrogen).  This segment was then inserted into 
the pVOTE.2 vector (B. Moss, NIAID, NIH) that contains the T7 promoter and gpt 
selection gene (Figure 2-1).   This final plasmid, pNB009, was transfected into HeLa 
cells, which were previously infected with vT7lacOI (B. Moss, NIAID, NIH).  The 
virus vT7lacOI is an engineered vaccinia virus that carries the T7 RNA polymerase 
and lac I genes.  The recombinant virus, denoted vNB009, resulting from 
homologous recombination of the pNB009 plasmid and vT7lacOI was plaque purified 
under selective pressure for the gpt gene, amplified in HeLa cells, and purified by 
sucrose cushion centrifugation.   
EGFP expression was verified by infection of HeLa cell monolayers with 
vNB009 at an MOI of 1.0 and induction with 1 mM IPTG in 6-well tissue culture 
plates.  Figure 2-2 shows images taken with a fluorescence microscope.  It is apparent 




Figure 2-2  Fluorescence Images of Infection with vNB009 
Panel A, HeLa cells infected with vNB009 and induced with 1 mM IPTG.  Panel B, 
cells infected with vNB009.  Panel C, cells without infection or induction.   
Images taken with a Kodak EDAS Digital microscopy system on a Leica DM IRB 






occurring when the cells are infected with the recombinant virus and induced with 
IPTG.   Cells that are infected but not induced, Panel B, show a very low level of 
green fluorescence, indicating that expression of EGFP is tightly controlled by the 
addition of the inducer.  Additionally, the absence of green fluorescence in the 
uninfected cells, Panel C, demonstrates a negligible background fluorescence of the 
HeLa cells.  Thus, EGFP expression using the VOTE system in vaccinia is possible 
and furthermore is tightly controlled by the presence of the inducing agent. 
2.4.2  Multiplicity of Infection Evaluation 
 Expression levels of EGFP at varying MOI were examined in 96-well culture 
plates (Figure 2-3). Several samples were taken during the protein production stage 
and the maximum level for each MOI was plotted.  The data show a sharp increase in 
the EGFP expression, which levels off upon approaching an MOI of 1.0.  This 
indicates that the expression may not appreciably increase with more than one virus 
particle per cell, which agrees with what is known about the inability of vaccinia 
virus to superinfect cells (Christen et al. 1990), such as is found with insect cell 
baculovirus (MOI>10) (Wang et al. 1993). 
2.4.3  Evaluation of MOI, Volume and Serum Concentration During Infection of 
HeLa Cells In Static Plate Culture  
MOI, volume, and serum concentration during the 1 h infection phase were 
evaluated using a set of factorial experiments which indicated that the best expression 
in 6-well plates was obtained at a volume of 0.5 ml, a serum concentration of 0% FBS 




Figure 2-3  EGFP Expression at Varying MOI 
Maximum EGFP expression levels in relative fluorescence units (RFU) obtained from 
infection and induction of HeLa cells in 96-well plate culture.  Eight samples were 
taken per MOI at several times after infection and the average of the maximum 
expression points are plotted with standard errors. 
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arranged as a 23 factorial treatment structure that was used to evaluate maximum 
EGFP production for all combinations of levels for each parameter (Table 2-1).  MOI 
was studied at levels of 0.5 and 1.5, volumes of 0.5 and 1.5 ml and serum 
concentrations of 2.5 and 5.0% FBS.  ANOVA analysis was performed on the 
maximum expression levels and no interactions among the variables were found, so 
the effects were considered separately.  The analysis showed that EGFP expression 
was statistically higher at an MOI of 1.5 than at an MOI of 0.5 (p=0.010), indicating 
that an examination of other MOIs would be needed to establish the MOI where 
maximum expression occurs. Additionally, the expression of EGFP was found to be 
statistically higher at a volume during the infection phase of 0.5 ml versus 1.5 ml 
(p=0.012).  This phenomenon has been seen by other researchers where lowering the 
volume is believed to enhance infection by increasing the rate of binding (Dee and 
Shuler 1997b).  Because 0.5 ml was the practical lower limit for infection in 6-well 
plates due to the thin layer of media that can cause the cells to dry out, it was the final 
level chosen and further evaluation of this parameter in 6-well plates was deemed 
unnecessary.  Recombinant protein expression was not found to be significantly 
different for the two serum concentrations tested during the infection phase 
(p=0.224).  This may have been due to the small range tested.  Another evaluation, 
with a wider range of serum concentration values, was needed to firmly establish the 
absence of an effect of serum.    
 A 42 factorial treatment structure was designed to test a wider range of both 
MOI and serum concentration during the infection phase in 6-well plates (Figure 2-4). 
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infection) 
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0.05 
0.5 0.5 2.5 3.66 
0.5 0.5 5.0 2.88 
1.5 0.5 2.5 4.03 
1.5 0.5 5.0 4.05 
0.5 1.5 2.5 2.20 
0.5 1.5 5.0 1.88 
1.5 1.5 2.5 3.57 






Figure 2-4  Evaluation of MOI and Serum Concentration During Infection 
Phase 
Maximum EGFP expression levels, in duplicate, obtained from infection and 
induction of HeLa cells in 6-well plates.  The pooled standard error obtained from 





















































and 4.0.  ANOVA analysis was performed on the maximum measured expression 
levels for each treatment combination.  Again, no significant interactions among the 
variables were found, therefore only main effects were considered.  The results show 
that the effect of serum was marginally significant (p=0.054) on the expression of 
EGFP, which indicates that lower levels of serum can be used during infection.  
Expression of EGFP was not found to be statistically affected by MOI within the 
region tested (p=0.278).  This finding agrees with the results suggested by the 96-well 
multiplicity of infection evaluation where a plateau of expression appeared to occur 
around an MOI of 1.0 and more than one infectious virus particle per cell may not 
significantly increase the level of EGFP expression. 
2.4.4  Microcarrier Selection Process 
An analysis of several microcarriers was performed, types and some descriptive 
details are displayed in Table 2-2.  The critical parameters for selection were the 
ability of the cells to attach to the microcarriers under agitation, the cell growth 
profile, the cell layering characteristics, and the maximum supported cell density.   
 The first experiment was performed in 6-well, low binding plates on a rotary 
shaker at 50 rpm.  Cells were seeded into plates in the presence of microcarriers and 
microscopic visualization of the attachment and spreading of the cells was performed.  
Once the cells were grown to confluency, a cell removal and counting procedure was 
followed to determine the ability of the microcarriers to allow an easy sampling 
procedure.  Based on these two criteria, four of the microcarriers were deemed 









Biosilon® 169159 (Nunc) Globular plastic 23.5 
Biosilon® 169191 (Nunc) Globular plastic 23.5 
Cultispher-G (Percell) Cross-linked gelatin 1.0 
Cultispher-S (Percell) Cross-linked gelatin 1.0 
Cytodex® 1 (Pharmacia) Cross-linked dextran, positively charged 1.0 
Cytodex® 3 (Pharmacia) Cross-linked dextran, collagen coated 1.0 
Cytopore™ 2 (Pharmacia) Macroporous, cross-linked dextran, positive charge 1.0 
FACT FC102-915 
(SoloHill) 




Copolymer, charged gelatin 
coated 20.0 
Gelatin C102-915 
(SoloHill) Copolymer, gelatin coated 20.0 
Gelatin C102-1521 
(SoloHill) Copolymer, gelatin coated 20.0 





the two Gelatin microcarriers from SoloHill).  The other eight microcarriers were 
retained for further evaluation.   
 These microcarriers were tested in 125 ml spinner flasks.  Flasks were 
prepared with microcarriers at the concentration recommended by each manufacturer 
and seeded with 1x105 cells/ml.  Samples were taken daily for cell count and viability 
measurements.  Three of the microcarriers tested, Cytodex® 1, Cytodex® 3 and 
Biosilon® 169191 lead to cell densities above 1.0x106 cells/ml (data not shown).  
These three microcarriers were evaluated further at a concentration of 20 g/l, (which 
was near the upper region of several of the brands tested), and with HeLa cells seeded 
to a density of 2x105 cells/ml.    All three microcarriers had exponential growth 
profiles (data not shown) with maximum cell densities of 3.7x106 ± 0.41x106, 3.0x106 
± 0.13x106 and 3.1x106 ± 0.32x106 for Biosilon® 169191, Cytodex® 1 and Cytodex® 
3, respectively.   The Biosilon® microcarriers were observed to allow the cells to form 
thick layers on the surface.  This was considered an undesirable characteristic because 
during infection, the inner cells would likely not be infected in the primary infection, 
and therefore may affect the overall expression kinetics.  Based on all these findings, 
and because the growth of HeLa on Cytodex® 3 during growth was slightly higher 
than on Cytodex® 1, Cytodex® 3 microcarriers were found to be the most appropriate 
microcarrier for this work. 
2.4.5  Infection and Expression from HeLa cells on Microcarriers 
EGFP expression from HeLa cells grown on microcarriers in spinner flasks at 
varying levels of MOI was examined (Figure 2-5).  The evaluated levels of MOI were 




Figure 2-5  MOI Effect on EGFP Expression from HeLa Cells Grown on 
Microcarriers in Spinner Flasks 
EGFP expression levels from HeLa cells on Cytodex® 3 microcarriers in 125 ml 
spinner flasks infected with vNB009 and induced with 1 mM IPTG.  Solid lines and 
filled symbols, intracellular EGFP measurements.  Dashed lines and open symbols, 
extracellular EGFP measurements.  Triangles, MOI=0.0; diamonds, MOI=1.0;  
circles, MOI=2.0; squares, MOI=3.0.   
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same volume ratio (media volume/cell) found best in monolayer culture and the 
infection was performed in serum-free media.  Glucose and lactate were measured 
throughout the growth and production phases (data not shown).  Up to 48 hpi, the 
levels were kept within an acceptable range for growth by feeding once at 24 hpi.  
After 48 hpi, most cultures showed a significant amount of cell lysis due to the 
cytopathic affects of the virus that made feeding the culture unrealistic.   
The expression results show that although the errors are fairly wide, maximum 
expression appears to occur at MOI 3.0.  This result was not found to be significantly 
different from MOI of 1.0 or 2.0 upon ANOVA analysis.  The large variance and the 
difference with the optimum MOI obtained from static culture experiments can be 
explained by the dynamic nature of the microcarrier system and by the fact that 
infection was done during late log phase for the microcarriers versus early log phase 
for the stationary cultures, where infection may be more efficient. Additionally, the 
method of cell counts on microcarriers may not be the most accurate, particularly at 
higher cell densities, leading to a higher variability.  In the future, other methods of 
cell counting will be investigated, such as nuclei counts (van Wezel 1973), to 
minimize this source of variation.  
Taking the above into consideration, the results show that both infection and 
expression occur with this method of production.  These parameters will be further 
studied in spinner flask microcarrier culture to optimize conditions and reduce the 




2.5  Conclusions 
The method of recombinant protein production described here has shown encouraging 
results. In particular, lowered volume during the infection phase helped to increase 
expression.  No serum during the infection phase was needed to ensure infection and 
expression of EGFP.  Additionally, an MOI near 1.0 was found to provide adequate 
infection and higher amounts of virus were found ineffective for increasing protein 
production in static plate cultures.  Future work will be directed at optimizing the 
conditions of expression in microcarrier cultures, including bioreactor cultures.  Other 
factors that may affect expression such as inducer concentration and timing of inducer 
addition will also be investigated.  To further exploit the versatility of this expression 
method, studies are underway to evaluate different cell lines such as HEK-293, BHK-
21, WI 38, or Vero infected with this vaccinia virus construct.  Other protein 
candidates that require complex post-translational processing are also being 
engineered into vaccinia constructs with the same promoter and expression elements 






CHAPTER 3:  Evaluation of Production Parameters with the 
Vaccinia Virus Expression System Using Microcarrier Attached 
HeLa Cells2 
3.1  Summary 
Parameters which affect production of the recombinant reporter protein, 
EGFP, in the T7 promoter based VOTE vaccinia virus-HeLa cell expression system 
were examined.  Anchorage dependent HeLa cells were grown on 5 g/l Cytodex® 3 
microcarriers, which were found to provide the optimum conditions for growth and 
infection.  Length of infection phase, inducer concentration and timing of its addition 
relative to infection were evaluated in 6-well plate cultures.  One hour infection with 
1.0 mM IPTG added at the time of infection provided a robust process.  Examination 
of the multiplicity of infection (MOI) in the dynamic environment of microcarrier 
culture indicated a need for an increase in the number of virus particles per cell to 5.0, 
higher than needed for complete infection in tissue flask culture.  Additionally, 
dissolved oxygen level and temperature during protein production phase were 
evaluated for their effect on EGFP expression in microcarrier spinner flask culture.  
Increased dissolved oxygen from 30% to 50%, and decreased temperature from 37°C 
to 31°C, showed a slight increase in production over the course of the production 
phase.  The level of production achieved with this system reached approximately 17 
µg EGFP/106 infected cells.     
                                                 
2 Bleckwenn NA, Bentley WE, Shiloach J. 2004. Evaluation of production parameters 





3.2  Introduction 
Vaccinia virus infection of HeLa cell culture has shown potential as a 
recombinant protein production method (Bleckwenn et al. 2003).  The current 
literature on growth and infection of HeLa cells in large-scale culture is limited 
(Barrett et al. 1989; Hu et al. 2000).  This study investigates microcarrier based 
culture of HeLa cells in spinner flasks to obtain basic information on how to best 
cultivate and infect these cells to express recombinant proteins.  Microcarriers 
provide solid support onto which anchorage dependent cells attach and grow 
(Croughan et al. 2000; Hawboldt et al. 1994; Iyer et al. 1999; Kang et al. 2000), but 
also the carriers can be suspended in culture medium and treated similarly to 
suspension culture, which makes this method of cultivation amenable to scale-up in 
conventional stirred tank bioreactors.   
Enhanced green fluorescent protein (EGFP) was used as a model protein with 
this viral expression system.  Green fluorescent protein has previously been used as a 
model for studying protein production with other expression methods, such as E. coli 
(Cha et al. 1999d; DeLisa et al. 1999), the insect cell or insect larvae-baculovirus 
system (Cha et al. 1999a; Cha et al. 1999b; Cha et al. 1999c; Cha et al. 1997; 
Laukkanen et al. 1996), and mammalian cell systems (Durocher et al. 2002; Sen et al. 
2003), because its expression levels are easily quantified via fluorescence 
spectrophotometry.  The VOTE vaccinia expression system (Ward et al. 1995) was 
used to control expression of the EGFP reporter gene, where the gene is introduced 
into the cytoplasm of the cell via the viral infection and protein is made upon 




a T7 promoter based system (Alexander et al. 1992) where all the control components 
are present in a single virus, unlike other vaccinia constructs that require dual 
infection (Fuerst et al. 1987; Hu et al. 2000).  Expression is tightly controlled by the 
addition of the inducing agent, IPTG, allowing for controlled expression of the 
protein of interest, which is advantageous when the protein to be produced is 
detrimental to the cell.   
Previous work in our lab evaluated several basic infection characteristics with 
this reporter virus in small-scale tissue flask experiments, which included multiplicity 
of infection (MOI), and both volume of medium and serum concentration during the 
infection phase.  Additionally, an examination of twelve commercial microcarriers for 
growth and cell sampling potential found that Cytodex® 3 possessed the most 
appropriate characteristics.  These conditions were used to infect microcarrier based 
spinner flask cultures at MOI from 0 to 3.0 where MOI of 3.0 reached 2.2 µg/106 
cells at infection.  This maximum was not statistically different from the maximums 
for MOI 1.0 or 2.0 and an evaluation of a wider range of MOI was suggested 
(Bleckwenn et al. 2003).   
The process parameters that can affect protein yield in a production system are 
numerous.  This study evaluates several key parameters for the establishment of cells 
and expression of recombinant proteins with the VOTE vaccinia expression system.  
The parameters evaluated include the concentration of microcarriers for the 
anchorage dependent HeLa cells, induction conditions, a wider range of multiplicity 




during the protein production phase, and temperature during the protein production 
phase.   
3.3  Materials and Methods 
3.3.1  Cell Line Maintenance and Expansion 
HeLa cells (ATCC CCL-2) were maintained in tissue culture flasks and were 
passaged every 3-4 days in Dulbecco’s modified Eagle’s medium with 4.5 g/l glucose 
(DMEM, Biosource, Camarillo, CA) and 10% fetal bovine serum (FBS, Biosource). 
In preparation for seeding well plates or microcarriers for experiments, confluent 
HeLa cells in multiple T-162 cm2 tissue culture flasks were harvested using cell 
dissociation solution (Hanks’ based, Invitrogen, Carlsbad, CA) and counted as 
described below.  Medium used for all experiments was composed of DMEM with 
4.5 g/l glucose without phenol red and supplemented with 4 mM L-glutamine 
(Biosource) and 10% FBS unless otherwise specified. 
Cytodex® 3 microcarriers (Amersham Biosciences, Piscataway, NJ) were 
prepared according to manufacturer’s instructions which involved washing with PBS, 
sterilization by autoclaving, and washing again with culture medium.  To seed the 
microcarriers, cells were harvested from tissue culture flasks and combined with 
Cytodex® 3 microcarriers in 250 ml siliconized spinner flasks with paddles (Bellco 
Glass, Inc., Vineland, NJ), at a final concentration of 1×105 cell/ml.  An initial 
reduced volume of 100 ml was used with an agitation profile of 30 seconds on at 50 
rpm and 20 minutes off, in a 37°C humidified incubator with 5% CO2 for four hours.  




working volume and the agitation was set to a constant 50 rpm.  Samples were taken 
daily for cell count and viability.  The cultures were fed as needed by allowing the 
cell bound microcarriers to settle, removing a portion of the spent medium and 
replacing it with an equal volume of fresh medium.   
3.3.2  Viral Stock Preparation 
Construction of the reporter virus, vNB009, containing the gene for EGFP 
with a C-terminal histidine tag (6×HIS), along with viral purification and titer 
determination of the stock was described previously (Bleckwenn et al. 2003).   
3.3.3  Cell Count and Viability Measurements  
A cell suspension sample for cell count and viability determinations from 
microcarrier cultures was prepared by centrifugation of a 1.0 ml sample at 300×g for 
5 minutes.  The supernatant was then aspirated and the sample washed with 0.5 ml of 
D-PBS with calcium and magnesium (Invitrogen).  The pellet was then resupsended 
in 0.5 ml of 1× trypsin-EDTA solution (Invitrogen) and incubated for 30 minutes at 
37°C with vortexing every 10 minutes.  An equal volume of DMEM+10% FBS was 
added and the sample was mixed.  The resulting solution was used for cell count and 
viability measurements using 0.4% trypan blue exclusion staining (Sigma, St. Louis, 
MO) on a hemacytometer.  
3.3.4  Nutrient and Metabolite Measurements 
Medium samples from experiments were used to measure glucose and lactate 
with a YSI 2700 Biochemistry Analyzer (Yellow Springs Instrument Co., Yellow 




3.3.5  Fluorescence Analysis of EGFP Expression 
Fluorescence measurements were made according to Bleckwenn et al. (2003).  
Briefly, pellet samples were resuspended and lysed in lysis buffer (100 mM Tris pH 
7.4, with 1× Complete protease inhibitor (Boehringer Mannheim GmbH, Germany) 
and 0.5% Triton X-100).  Fluorescence measurements of the supernatant from pellet 
lysis and culture medium were made in 96-well black plates (Fisher Scientific, 
Pittsburg, PA) using a SpectraMax Gemini fluorescence spectrophotometer 
(Molecular Devices, Sunnyvale, CA) with excitation at 485nm, emission at 512 nm 
and an auto cutoff filter of 495 nm against standards of rEGFP (Clontech BD 
Biosciences, Palo Alto, CA). 
3.4  Results 
3.4.1  Microcarrier Density Evaluation  
The effect of Cytodex® 3 microcarrier concentration on viable cell density and 
coverage of the carriers was initially tested at 5, 10, 15 and 20 g/l in 200 ml spinner 
flask cultures in duplicate, but did not show significant differences in maximum cell 
density (P= 0.64, data not shown).  A lower range of microcarrier concentrations was 
then tested at 2, 4, 6 and 8 g/l to determine the optimum microcarrier density.  Viable 
cell density as a function of time is shown in Figure 3-1 for these carrier 
concentrations.  The 2 g/l concentration appeared to lag behind the others at about 
120 hours after seeding and the carriers were completely confluent upon visual 
inspection (data not shown). The concentrations of 4, 6, and 8 g/l follow 




Figure 3-1  Growth of HeLa Cells on Cytodex® 3 Microcarriers 
Viable cell densities from spinner flask cultures (200 ml) of microcarrier attached 


































maximum cell density, around 2.5 to 3.5×106 cells/ml.  Visual inspection of the 
coverage of cells on the carriers (data not shown), revealed that a concentration 
between 4 and 6 g/l appeared to allow single layer growth, while reaching confluency 
between 150 and 175 hours after seeding. 
3.4.2  Effect of Infection Duration on EGFP Production  
The effect of the length of the infection phase on EGFP production is seen in 
Figure 3-2.  The infection was carried out in a reduced volume of serum-free medium, 
0.5 ml, with 1.0 mM IPTG in 6-well plate culture where the cell concentration at 
infection was 2.00±0.13×106 cells/well.  Virus vNB009 was added to the cells to 
infect at an MOI of 1.0.  Plates were incubated, for 15, 30, 60, 120, or 240 minutes, at 
which time medium was added to bring the volume to 2.5 ml with the serum 
concentration brought to 10% FBS and inducer to 1.0 mM IPTG, completing the 
infection phase.  Infected cells were incubated for 36, 42 and 48 hours for each 
infection length (e.g. 3 samples, 5 infection lengths). The maximum intracellular 
EGFP expression levels of the three time points sampled for each infection length 
were averaged for duplicate wells.  The results show a minimum infection time of one 
hour for maximum protein expression.   
3.4.3  Effect of IPTG Concentration and Timing of Its Addition Relative to 
Infection on EGFP Production 
A 6×3 factorial treatment structure experiment was performed on HeLa cells 
in 6-well plates.  The concentrations of IPTG inducer tested were 0.0, 0.1, 0.5, 1.0, 




Figure 3-2  Effect of Infection Duration on Reporter Protein Expression 
Six-well plate cultures of HeLa cells were infected at an MOI of 1.0 for varying 









































at the time of infection, or one hour after infection.  The cells were prepared and 
infected in the same manner as previously described, at an MOI of 1.0 in a reduced 
volume of serum-free medium, and for 1 hour as found from Figure 3-2.  At the end 
of the one hour infection phase, the medium was increased and serum added to 10% 
FBS with the appropriate IPTG level.  The maximum intracellular expression levels 
found for each well were averaged over duplicate wells (Figure 3-3).  There was no 
interaction between the two tested parameters (P=0.12) and no significant differences 
were found between the times evaluated for addition of the inducer (P=0.82).  
However, the differences in IPTG concentration were statistically significant 
(P<0.0001) and maximum expression levels were achieved with IPTG concentrations 
of 0.5 mM and above.   
3.4.4  Multiplicity of Infection in Microcarrier Culture Spinner Flasks  
Multiplicity of infection was evaluated in triplicate spinner flask cultures of 
microcarrier attached HeLa cells.  Cultures were infected 5 days after seeding when 
the cell density was 1.22±0.083×106 cells/ml.  The cells were washed with serum-free 
medium, the volume was reduced to 70 ml for infection in serum-free medium 
containing 1.0 mM IPTG.    Trypsinized vNB009 virus was then added to the culture 
and the flasks were incubated at 37°C, 5% CO2 at 50 rpm for one hour.  At the end of 
this infection phase, medium, FBS and IPTG were added to a final volume of 200 ml, 
10% FBS, and 1.0 mM IPTG.  Samples of pellet, containing cells and carriers, and 
supernatant were taken up to 66 hpi.  Medium (100 ml) was exchanged with fresh 
medium at 24 hpi to maintain the level of glucose above 1.0 g/l and the concentration 




Figure 3-3  Effect of IPTG Concentration and Timing of Its Addition Relative to 
Infection on Protein Expression 
A factorial treatment structure design of experiment was used to determine the effects 
IPTG concentration and the timing of its addition relative to infection on protein 
expression.  The timing of addition is separated into three separate lines as the 












































production phase are depicted in Figure 3-4, where intracellular levels are shown in 
Panel A and extracellular levels in Panel B.  Although there are not significant 
differences in the maximum intracellular expression levels for MOI 0.5 and above (P 
≥ 0.36), it appears that MOI 5.0 and 10.0 were slightly better in the initial 40 hours, 
after which 0.5 and 1.0 increased to the same levels.  The maximum obtained was 2.6 
µg/106 infected cells.  The extracellular levels of EGFP began to increase as the 
intracellular values began to peak and then decline.  Their levels were approximately 
equal for MOI 0.5 to 10.0, but were lower for MOI 0.1. 
3.4.5  Effect of Dissolved Oxygen Level on Protein Production 
The effect of dissolved oxygen concentration on protein expression was 
studied in spinner flask cultures infected at MOI 5.0 for one hour with 1.0 mM IPTG 
added at infection.  At the end of the infection phase, medium was added to bring the 
culture volume to 200 ml with 10% FBS and 1 mM IPTG.  Each flask was mixed 
well and varying amounts of culture (including medium, cells, and microcarriers), 
were removed to achieve volumes of 50, 100, 150, and 200 ml while maintaining the 
same microcarrier concentration and cell density.  These volumes correspond to 
surface area to volume (SA/V) ratios of 1.08, 0.54, 0.36, and 0.27 cm-1, respectively, 
and allow for a rough comparison of changing dissolved oxygen levels.  Samples 
from the cultures for metabolite and protein analysis were taken up to 66 hpi and 
feeding of the culture was performed at 24 hpi.  Figure 3-5 shows the intracellular 
expression levels.  From this data, the maximum level of production was found with 
an SA/V ratio of 0.54 cm-1 at 3.13 µg/106 infected cells.  Both higher and lower SA/V 




Figure 3-4  EGFP Expression vs. MOI in Microcarrier Spinner Flask Cultures 
200 ml spinner flask cultures containing HeLa cells attached to microcarriers were 








































































Figure 3-5  Effect of Dissolved Oxygen Level on Protein Production 
Different surface area to volume ratios were used to approximate differences in 
dissolved oxygen level.  Cultures of volume 50, 100, 150, and 200 ml were grown in 







































3.4.6  Effect of Temperature on Protein Production  
An evaluation of process temperature during the protein production phase was 
made in spinner flask cultures containing microcarrier attached HeLa cells.  Cells 
were seeded onto microcarriers and infected as before at an MOI of 5.0 with 1.0 mM 
IPTG, then brought to 200 ml after the one hour infection phase.  The temperatures 
were then adjusted to 25, 28, 31, or 34°C, with 37°C (± 0.5°C) tested previously in 
the dissolved oxygen experiment.  The intracellular expression profiles of the reporter 
protein for the different temperatures followed the same general trend, shown in 
Figure 3-6.  At 34°C maximum expression was achieved ~48 hpi, while the 
maximum for 31°C occurred ~80 hpi, and later for 28 and 25°C.   The highest 
expression level was achieved at 31°C, at 17.2±2.24 µg/106 infected cells. 
3.5  Discussion 
The protein production potential of the HeLa cell-VOTE vaccinia expression 
system and its initial characterization were established in our lab (Bleckwenn et al. 
2003).  While the previous study demonstrated to potential for HeLa-VOTE vaccinia, 
several factors remained unexamined.  Specifically, this article describes the 
systematic evaluation of several key parameters affecting growth, and production: 
microcarrier concentration, infection time and duration, and inducer concentration 
and timing of its addition relative to infection.  Also, while our previous study 
identified Cytodex® 3 as most promising, the current work found that 5 g/l of these 
carriers was sufficient in terms of surface area for cell growth and spatial expansion 




Figure 3-6  Effect of Temperature on Protein Production 
Temperatures were adjusted in microcarrier based spinner flask cultures after the 








































for the microcarrier densities evaluated, visual inspection of cell coverage on the 
microcarriers, although somewhat subjective, was critical to this evaluation.   
Infection parameters influencing protein expression levels were evaluated in 
6-well plate cultures which included infection duration, inducer concentration, and 
timing of inducer addition relative to the time of infection.  These small-scale 
experiments were more amenable than microcarrier spinner flask cultures for testing a 
larger number of conditions.  The length of the infection phase is critical for most 
viruses to ensure binding of the virus particles and entry into the cells (Chillakuru et 
al. 1991; Locker et al. 2000; Petricevich et al. 2001; Vanderplasschen et al. 1998; 
Vanderplasschen and Smith 1999).  The infection duration experiment performed 
here resulted in an optimal length of infection of one hour, which coincides with the 
value found by other researchers with other vaccinia infection systems (Chillakuru et 
al. 1991; Hu et al. 2000).   
The concentration of the induction agent, IPTG, and the timing of its addition 
relative to infection in this system both play a critical role in protein expression, as 
was evident by the results in Figures 3-2 and 3-3.  Since these two parameters may be 
linked and interact with one another, they were tested together in a 6×3 factorial 
treatment structure experimental design.  Interestingly, no interaction was found 
between inducer concentration and induction time for the ranges tested.  Further, no 
significant difference was found for the timing of inducer addition relative to 
infection, indicating that the transfer of IPTG to the cells was not limiting for the 




In some cases, certain foreign proteins may be detrimental to the cell and 
could affect protein production and cell culture health, possibly requiring a delayed 
induction time to reach maximum expression levels, but this is not the case for EGFP.  
In addition, the ability to control the time of induction may be beneficial for 
secondary infection processes (Bentley et al. 1994; Hu and Bentley 2000; Hu and 
Bentley 2001), where the culture is initially infected at a very low MOI in order to 
conserve viral stocks.  The small number of initially infected cells at low MOIs would 
serve as virus production factories, rather than protein production factories, to 
produce the virus particles that will infect the remainder of the culture.  To maximize 
the production of virus particles and conserve resources for the infected cells, 
induction of protein expression could be delayed until secondary infection of the 
culture has occurred.  The minimum IPTG concentration required for maximum 
expression showed little difference for concentrations higher than 0.5 mM.  Although 
0.5 mM IPTG was found to be sufficient, the level of expression drops off 
significantly below 0.5 mM IPTG, thus, to ensure that maximal levels of protein 
production are achieved, a value of 1.0 mM was chosen for all future studies.  
Additionally, for convenience, since the timing of inducer addition did not affect 
expression, adding the induction agent at the time of infection was chosen for all 
subsequent work.   
Multiplicity of infection is another parameter that can affect protein 
production.  For insect cells, superinfection of the cells (infection with more than one 
virus particle per cell) can affect the level of protein production (Hu et al. 2003; 




multiple infection past the first hour of exposure to virus (Christen et al. 1990), and 
using an MOI greater than 1.0 did not affect the expression in monolayer plate culture 
(Bleckwenn et al. 2003).  The dynamic nature of microcarrier culture, however, may 
alter the infection kinetics from those seen in plate culture.  Similar results have been 
seen in insect cells in plate versus spinner flask culture (Dalal and Bentley 1999; Dee 
and Shuler 1997a).  Our work with microcarrier based HeLa cell culture found that an 
MOI of 5.0 yielded the highest intracellular expression of EGFP, and although MOI 
10.0 initially followed the same rate of production, the level did not reached the same 
maximum due to an earlier decline in expression, possibly due to an increased 
cytopathic effect and cell lysis.  Lower MOIs did not appear to have the same rate of 
expression as MOI 5.0, and therefore, 5.0 pfu/cell was chosen for all microcarrier 
based work to ensure complete, simultaneous infection and maximal expression of the 
recombinant protein.  Other researchers have also used higher MOIs for vaccinia 
virus infection in large-scale HeLa cell packed bed (Hu et al. 2000) or Vero cell 
microcarrier culture (Barrett et al. 1989). 
Process parameters such as dissolved oxygen and temperature, may also affect 
the final yield of protein.  Providing an ample supply of oxygen is crucial to 
maintaining cell health and protein production and may also affect proper post-
translational processing as was seen with the insect cell baculovirus system  
(Donaldson et al. 1999; Zhang et al. 2002b) and other expression systems (e.g. 
hybridomas, CHO, etc. (Kunkel et al. 2000; Kunkel et al. 1998)).  To determine 
whether supplying more oxygen to the cells would help increase production of the 




dissolved oxygen level was varied by adjusting the surface area to volume ratio while 
maintaining constant cell and microcarrier densities.  The results suggest that 
increasing DO increases the level of protein production but only to a certain point 
(e.g. more production obtained at 0.54 cm-1). The level of dissolved oxygen during 
the production phase can play an important role in the health of cells, particularly 
while they are burdened from a viral infection.  Interestingly, vaccinia virus will shut 
down host cell protein production in order to dedicate more resources for producing 
its own proteins and progeny virus (Cacoullos and Bablanian 1993), and in our case, 
production of the recombinant protein.  In utilizing a viral production system, it is 
necessary to reduce the burdens caused by infection and the cytopathic effects of the 
virus as much as possible, to allow for more time to produce the recombinant protein 
before the cells die and lyse. Other researchers using the insect cell baculovirus 
system found optimum levels of DO for protein production in their respective 
systems, but some also found that high levels of DO decreased protein production due 
to an increase in protease activity (Hu and Bentley 1999; Lindsay and Betenbaugh 
1992; Naggie and Bentley 1998).  
Concerning temperature, most mammalian cell lines grow best at 37°C 
(Freshney 2000), and significant deviations above this temperature are devastating to 
the cells.  Lower temperatures are tolerable, but the cells tend to grow slower.  It has 
been found that virus systems such as Semliki Forest Virus (SFV) and adenovirus 
(AV) both produce higher amounts of protein when production occurs at a lowered 
temperature (Jardon and Garnier 2003; Schlaeger and Lundstrom 1998). Insect cell 




decreased temperatures (Andersen et al. 1996; Gotoh et al. 2004).  It was suggested 
with the SFV system that the lower temperature reduces cytopathic effects of the viral 
infection and allows the cells to remain healthier and producing protein for a longer 
period of time, resulting in higher yield.  In the present work, temperature was 
adjusted after the infection phase to ensure that this change had no affect on the 
kinetics of infection, only on protein production and cytopathic viral effects.  
Importantly, lowering the temperature to 31°C increased the specific yield six-fold 
over the 37°C culture in microcarrier based spinner flasks.   
It is important to note that dissolved oxygen and temperature are not 
independent.  By changing the SA/V, changes in the soluble carbon dioxide can occur 
which could affect the culture pH.  Additionally, changing the incubation temperature 
of spinner flasks, without DO control, affects the level of dissolved oxygen.  
Translating the results obtained from these spinner flask cultures to large-scale 
culture cannot be made directly because altering these parameters in this way cannot 
isolate the variable being studied.  In a more controlled environment, such as a 
bioreactor, the result of changing DO and temperature could be tested in isolation 
from other variables.  The conditions found here, therefore, are sufficient to guide 
further work at the reactor scale. 
3.6  Conclusions 
In summary, the results of the various parameter experiments shown here 
suggest that the optimum conditions for establishing the HeLa cells are to seed and 
grow them on 5 g/l Cytodex® 3 microcarriers.  Infection parameters were also refined 




resulted in an infection at MOI 5.0 for one hour with inducer added at the time of 
infection at a concentration of 1.0 mM IPTG.   By increasing the dissolved oxygen 
through adjustment of the SA/V, and lowering the temperature of the culture to 31°C, 
increases in protein production were seen.  The maximum level of protein production, 
under the conditions tested, lead to a yield of 17-18 µg intracellular EGFP/106 




CHAPTER 4:  Vaccinia Virus Production of Recombinant 
Proteins in a Microcarrier Based Mammalian Cell Bioreactor3 
4.1  Summary 
The HeLa cell-vaccinia virus expression system was evaluated for the 
production of recombinant proteins (enhanced green fluorescent protein (EGFP) and 
HIV envelope coat protein gp120) using microcarriers in 1.5 l perfused bioreactor 
cultures. Perfusion was achieved by use of an alternating tangential flow device 
(ATF), increasing the length of the exponential phase by 50 hours compared to batch 
culture and increasing the maximum cell density to 4.4×106 cell/ml.  A seed train 
expansion method using cells harvested from microcarrier culture and reseeding onto 
fresh carriers was developed.  Enhanced green fluorescent protein (EGFP) was first 
used as a model protein to study process parameters affecting protein yield, 
specifically dissolved oxygen (DO) and temperature during the production phase.  
The highest level of EGFP, 12±1.5 µg/106 infected cells, was obtained at 50% DO 
and 31°C.  These setpoints were then used to produce glycoprotein gp120, which was 
purified and deglycosylated, revealing a significant amount of N-linked 
glycosylation.  Also, biological activity was assayed, revealing an ID50 of 3.1 µg/ml, 
which is comparable to previous reports.   
                                                 
3 Bleckwenn NA, Golding H, Bentley WE, Shiloach J. 2004. Vaccinia virus 
production of recombinant proteins in a microcarrier based mammalian cell 




4.2  Introduction 
Recombinant protein expression from cell culture can be accomplished by 
stable or transient integration of DNA into the host cells. Viral vectors provide one 
such method of efficient transient expression and have been used widely (e.g. insect 
cells, insect larvae).  The baculovirus has proven to be very effective at producing 
large quantities of foreign proteins (Bentley et al. 1994; Cha et al. 1999c; Chung et al. 
1993; Licari and Bailey 1991; Lindsay and Betenbaugh 1992; Wickham and 
Nemerow 1993).  Generally though, complex proteins made with this system are not 
processed in the same manner as in mammalian cells, without significantly altering 
the host cells’ post-translational processing machinery (Ailor and Betenbaugh 1999; 
Ailor et al. 1999; Ailor et al. 2000; Fang et al. 2000; Percival et al. 1997).  When 
proper post-translational modifications are necessary, for example, often for proteins 
used as therapeutic agents (Eckhardt et al. 2002; Fenouillet and Jones 1996; Li et al. 
1993), it may be more advantageous to use a mammalian derived host cell line.    
Our lab has postulated that a viral system used with mammalian cell culture, a 
more complex system with innate capabilities for complex post-translational 
processing, might also lead to increased levels of protein production compared to 
stable integration of foreign DNA into the host cell.  Vaccinia virus, an orthopoxvirus 
related to the virus that causes Smallpox, was chosen as the viral vector due to its 
unique characteristics.  This virus has a wide host range (Broder and Earl 1999) and 
its own transcriptional machinery is brought into the cytoplasm of the infected cell 
(Moss 1996).  This feature allows the recombinant protein to be transcribed in the 




mRNA transcripts.  Bypassing these potentially rate-limiting transport steps during 
cell line development and protein production may increase the ability of this system 
to produce larger proteins than those systems which do not have this feature.  
Additionally, it is speculated that the capacity for gene insertions in vaccinia virus is 
up to 25,000 bp of DNA, exceeding the capacity of other mammalian expression 
vectors (Moss 1991; Smith and Moss 1983).  Comparing short term methods of 
production, viral vectors are considered more efficient than DNA transfection 
methods and can be used to infect a large volume of cell culture (Moss 1991). 
Recombinant proteins produced with vaccinia can undergo N- and O-linked 
glycosylation, phosphorylation, myristylation, proteolytic cleavage, polarized 
membrane and nuclear transport, and secretion (Moss 1991).  Researchers have used 
the vaccinia expression system to infect many cell types for production of proteins 
including a nerve growth factor (NGF) (Edwards et al. 1988) and Factor VIII 
(Pavirani et al. 1987), wherein the processing modifications of the cell lines were 
examined.  For both proteins, cell lines were identified which produced and properly 
processed proteins.   
Vaccinia virus has been studied for many years as a method of gene delivery 
in animal species and humans (Brochier et al. 1991; Cooney et al. 1991; Cooney et al. 
1993; Graham et al. 1992; Hanke et al. 2002; Hanlon et al. 1998; Kieny et al. 1984; 
McAneny et al. 1996; McClain et al. 2000; Moss 1996; Wiktor et al. 1984; Zajac et 
al. 2003) and as a research tool for protein production in small-scale (Arp et al. 1996; 
Chakrabarti et al. 1997; Davis et al. 1996).  Few researchers have investigated the 




various promoter elements.  A 40 l bioreactor with Vero cells attached to 
microcarriers was used to produce gp160, the full length form of the HIV-1 envelope 
coat protein that contains gp120 (Barrett et al. 1989).  A packed bed bioreactor (1.6 l) 
utilizing a T7 based co-infection scenario with HeLa cells was used to produce gp120 
previously in our lab (Hu et al. 2000).   Both studies achieved production of these 
HIV envelope proteins at 2-3 µg/106 cells. In this report recombinant vaccinia virus 
containing the gene for the reporter protein enhanced green fluorescent protein 
(EGFP) in an inducible T7 promoter based virus construct called the VOTE system 
(Ward et al. 1995) was tested for its potential in large-scale production.  This protein 
was produced earlier at 2.2 µg EGFP/106 cells at infection in spinner flask culture of 
HeLa cells attached to microcarriers (Bleckwenn et al. 2003), similar to the levels 
found by Hu and Barrett (Barrett et al. 1989; Hu et al. 2000).    
 Growth of anchorage dependent mammalian cells at large-scale can be 
accomplished through the use of special reactors such as stacked plate systems, 
packed bed or hollow fiber bioreactors or with microcarriers in a standard stirred tank 
bioreactor (Bleckwenn and Shiloach 2004).  Microcarrier cultures were chosen for 
this work because, once seeded with cells, the carriers are treated similarly to 
suspension culture.  However, media replacement, generation, and harvest of the 
large number of cells needed for seeding the bioreactor may be difficult. 
The work presented here concentrates on defining the proper conditions 
required for the production of recombinant protein from the HeLa cell-vaccinia 
system with microcarrier culture in a stirred tank bioreactor. Methods for media 




then used to produce gp120.  Production and analysis of these proteins provides new 
insight on the potential of vaccinia for production of complex human proteins.   
4.3  Materials and Methods 
4.3.1  Cell Maintenance and Expansion 
HeLa cells (ATCC CCL-2) were used for all production experiments.  BS-C-1 
cells (ATCC CCL-26) were used for titer determination of viral stocks.  Both were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 4.5 g/L glucose 
(Biosource, Camarillo, CA) supplemented with 10% fetal bovine serum (FBS, 
Biosource).  The cells were grown in tissue culture flasks and passaged every 3-4 
days.  Cells used for experiments were prepared by expanding the culture to multiple 
tissue culture flasks and were harvested using Hanks’ based cell dissociation solution 
(Invitrogen, Carlsbad, CA) and counted as described below.  Medium used for all 
experimental conditions was composed of DMEM with 4.5 g/L glucose without 
phenol red and supplemented with 4 mM L-glutamine (Biosource) and 10% FBS 
unless otherwise specified.   All bioreactor work included 100 units/ml Penicillin-
Streptomycin (PS, Invitrogen, Carlsbad, CA) to reduce the chance of contamination.  
4.3.2  Cell Count and Viability Measurements 
Cell suspension samples were used to measure cell count and viability using 
0.4% Trypan Blue exclusion staining (Sigma, St. Louis, MO) on a hemacytometer.  
To obtain the suspension samples from the anchorage dependent cells, cells from 
tissue culture flasks were harvested using cell dissociation solution and a suspension 




to be removed from the carriers before counting and this was accomplished by the 
following trypsinization procedure.  A sample of the microcarrier was centrifuged at 
300×g for 5 minutes.  The supernatant was aspirated and the pellet washed with D-
PBS with 0.9 mM calcium chloride and 0.5 mM magnesium chloride.  The pellet was 
then resupsended in 1× trypsin-EDTA solution and incubated at 37°C for 30 minutes 
with vortexing every 10 minutes.  This sample was mixed with an equal volume of 
DMEM+10% FBS and was then used as the cell suspension sample for counting 
procedures.  A sample of the culture with cells still attached to the carriers was 
visualized via microscopic observation at 100× magnification to estimate the percent 
coverage of the cells on the carriers. 
4.3.3  Nutrient and Metabolite Measurements  
Samples of culture medium were taken from the spinner flasks or bioreactors 
and glucose and lactate were measured on a YSI 2700 Biochemistry Analyzer 
(Yellow Springs Instrument Co., Yellow Springs, OH).   
4.3.4  Seeding and Growth of HeLa Cells on Microcarriers in Spinner Flasks 
Cytodex® 3 microcarriers (Amersham Biosciences, Piscataway, NJ) were 
hydrated and washed in PBS and sterilized for 30 minutes at 121°C.  The carriers 
were then washed in sterile PBS and finally in culture medium.  Spinner flask (250 ml 
Bellco, siliconized) cultures were seeded with 1.0×105 cell/ml onto 5 g/l Cytodex® 3 
microcarriers.  The initial volume of medium was reduced to half (100 ml) and an 
intermittent stirring profile (30 sec on and 20 min off for 4 h) was used to attach the 




and the stirring speed was maintained at 50 rpm in a 5% CO2, humidified, 37°C 
incubator.  Cultures were grown and monitored daily for cell density, viability, 
percent coverage of the carriers, glucose and lactate.   
The cultures used in microcarrier seeding were prepared and grown as 
described above with 20×106 HeLa cells seeded onto 5 g/l Cytodex® 3 in 200 ml of 
culture.  These were grown for five days until almost confluent.  The microcarriers 
were then allowed to settle for five minutes, after which 150 ml of medium was 
removed.  The culture was then washed twice with PBS and again reduced to 50 ml 
total volume.  Trypsin-EDTA solution was added (0.25% (v/v) trypsin and 1 mM 
EDTA final).  The spinner flasks were then returned to agitation at 50 rpm for 20 min.  
50 ml medium with 10% serum was then added and the flasks incubated for another 
10 minutes.  Samples were removed and the freely suspended cells counted.  20×106 
cells from these suspensions were then seeded into new spinner flasks with 5 g/l 
Cytodex® 3 microcarriers in the standard reduced volume with agitation profile for 
seeding.  These cultures were monitored for cell count, viability and estimation of 
percent coverage of the carriers.  
4.3.5  Seeding Microcarriers with HeLa Cells and Growth in Bioreactor 
Cytodex® 3 microcarriers (5 g/l) were used for all reactor experiments and 
HeLa cells were seeded at 1.5×105 cells/ml in DMEM+10% FBS into a 2.2 l 
siliconized bioreactor vessel (Bioflow 3000, New Brunswick Scientific, New 
Brunswick, NJ).  The initial seeding volume was reduced to ~500 ml in the reactor 
and an agitation profile was programmed to control the pitched-blade impeller at 50 




at 15 rpm (where the carriers would settle).  This was continued for four hours until 
the cells were attached to the carriers.  At the end of this seeding stage, medium was 
brought to 1.5 l and the agitation adjusted to a constant 50 rpm.  The DO and pH were 
controlled at 30% (air saturation) and 7.2 by altering the headspace gas composition.  
Temperature was controlled at 36.5°C. The cells were allowed to grow in batch mode 
for two days, after which perfusion feeding was used to maintain the glucose above 
1.0 g/l and the lactate below 2.0 g/l.  Generally, exchanged medium volumes ranged 
from zero, on the first day of seeding, to half a reactor volume per day, on day five 
before infection, or up to one reactor volume per day for uninfected cultures.   This 
was accomplished through the use of the ATF™ System (ATF, Refine Technology 
Inc., East Hanover, NJ) with a mesh screen module and controlling the filtrate pump 
speed which removed spent medium through the ATF (see Results).  That is, fresh 
medium was added when the level controller signaled to the feed addition pump, 
maintaining a constant reactor volume.   
4.3.6  Infection of Bioreactor Cultures and Protein Production 
Viable cell density determinations were made prior to infection to determine 
the total number of cells in the culture.  Medium without serum, but containing 1.0 
mM IPTG, was exchanged with the culture medium and the volume reduced to ~400 
ml using the ATF.  These medium manipulations took ~1 h.  The amount of virus 
needed for infection at an MOI of 5.0 was trypisinized for 30 minutes at 37°C with 
vortexing every 10 minutes and then diluted in 100 ml of serum-free medium with 1.0 
mM IPTG.  The diluted virus was added to the reactor and the infection phase, in the 




to 1.5 l and the serum concentration back to 10% FBS.  The ATF was run during and 
after infection, but without drawing off filtrate until step feeding occurred at either 24 
or both 24 and 48 hours post infection (hpi).  Samples were taken for analysis.   Cell 
density and viability measurements after infection were not possible because the 
method of removing the cells from the carriers was too harsh for the fragile, infected 
cells, resulting in cell lysis and inaccurate determinations.  Measurements of EGFP 
fluorescence were made on culture medium and lysed pellet samples according to 
Bleckwenn (Bleckwenn et al. 2003).   
4.3.7  gp120 Vaccinia Virus Construction 
Plasmid pTM-DHgp120H (kindly provided by Michael Cho, (Lee et al. 
2000)) was used to create the gp120 containing vaccinia virus following methods 
similar to those described in Bleckwenn (Bleckwenn et al. 2003).  Specifically, Nde I 
(New England Biolabs, Beverly, MA) was used to partially digest plasmid pTH-
DHgp120H to cleave the plasmid at the beginning of the gp120 gene.  The reaction 
mixture was heated to 65°C to stop the reaction and inactivate Nde I, after which the 
mixture was digested with Xho I (New England Biolabs) to completion.  Additionally, 
plasmid pVOTE.2 was cleaved with Nde I and Xho I in sequential digests.  The 
pVOTE.2 digested plasmid was treated with CIP (New England Biolabs).  A 0.9% 
agarose gel was run with the digest samples and the 1536 bp band from pTM-
DHgp120H and 6299 bp band from pVOTE.2 were extracted and purified.  A ligation 
reaction was then performed with these fragments, and the resulting plasmid 
transformed into competent E. coli Top 10F′.   Plasmid pNB014 was isolated from 




fragment sizes.  Additionally, the plasmid was used for PCR reactions to verify the 
gene sequence. 
Virus vNB014 containing the gp120 and histidine tag (6×HIS) with the VOTE 
elements was created by the following method.  A T-25cm2 flask of confluent HeLa 
cells was infected at an MOI of 0.05 with vT7lacOI for two hours at 37°C in a 5% 
CO2 humidified incubator with periodic rocking.  At the end of the infection, 5 µg of 
pNB014 plasmid, containing the gp120-6×HIS gene, was transfected using 
Lipofectamine Plus (Invitrogen).  The cells were incubated for 3-4 days and then 
recombinant virus was harvested by scraping, centrifuging, and resuspending in 0.5 
ml serum-free medium (DMEM, Biofluids).  The suspension was subjected to three 
cycles of freeze-thaw in a dry ice-ethanol and 37°C waterbath.  The virus preparation 
was then amplified under selective pressure with MPA (25 µg/ml), xanthine (250 
µg/ml) and hypoxanthine (15 µg/ml) (all from Sigma, St. Louis, MO) in a flask of 
HeLa cells and harvested after 3 d infection.  The resulting virus was harvested and 
two rounds of plaque purification on confluent monolayers of HeLa cells with 
selective agents in Minimal Essential Medium (Invitrogen) +10% FBS and 1% 
agarose were performed to isolate the recombinant virus (Bleckwenn et al. 2003).  
Amplification of the virus plaque was performed in 12-well, T-25 cm2, and T-162cm2 
flasks under selective pressure and then finally amplified to ten T-162cm2 flasks with 
no selective agents.  The purity of the recombinant virus was verified by infecting 12-
well culture of HeLa cells and isolating the DNA.  PCR reactions of the resulting 
DNA were performed with primers 5′−CAT ATG AGA GTG ATG GGG ATC AGG 




TCT −3′ reverse to verify the presence of the gp120-6×HIS gene segment and with 
primers 5′− CGG TGT CTG TAT GAT CTT CTA C −3′ forward and 5′− TGA GTG 
CTT GGT ATA AGG AGC CC −3′ reverse, (designed by Terri Shors NIAID, NIH), 
to verify the presence of the entire insert containing all of the VOTE promoter control 
elements.  The amplified virus was then purified by 36% sucrose gradient 
centrifugation and resuspended in buffer (10 mM Tris-Cl, pH 9.0).  Titer 
determination was made in triplicate on confluent monolayers of BS-C-1 cells by 
serial dilution of the stock and duplicate plating of a range of dilutions.  Plaques were 
counted and the concentration determined to be 1.93×1010 pfu/ml.  Viral stock 
vNB014 was frozen at -70°C for storage.  Figure 4-1 depicts a schematic 
representation of the virus construction in Panel A and Western blot verification of 
gp120 expression in Panel B.  
4.3.8  gp120 Protein Purification on Nickel Column 
Supernatant from bioreactor cultures were collected at 96 hpi and frozen.  
Supernatant (200 ml) was thawed to 4°C and NP-40 was added to a concentration of 
0.5% to inactivate virus particles and NaH2PO4 (20 mM) and NaCl (500 mM) were 
added.  The solution was stirred overnight at 4°C.  A Hi-Trap HP 1 ml column 
(Amersham Biosciences, Piscataway, NJ) was used on an ACTAprime purification 
unit (Amersham Biosciences).  The column was washed with wash buffer (containing 
50 mM NaH2PO4 20 mM NaCl and 20 mM imidazole).  The protein was then eluted 
with a 10 ml gradient from 20 to 500 mM imidazole.  Fractions (0.5 ml) were 
collected.  The column was then finally washed with wash buffer.  Absorbance 




Figure 4-1  gp120 Virus Construction and Expression Verification 
pNB014 plasmid was constructed as shown (Panel A) and used for transfection of 
HeLa cells infected with vT7lacOI to generate recombinant virus containing the 
gp120 gene.  Isolation, amplification, purification, and titering lead to the generation 
of a viral stock, vNB014 (see Methods).  Panel B shows a Western blot of supernatant 
samples from 6-well plate cultures of HeLa cells infected with either vNB014, 
containing the gp120 gene in the right lane, or another virus without the gp120 gene 
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location of the protein in 96-well UV-plates (Coring Costar, Acton, MA).  The 
fractions were pooled appropriately and run on reducing SDS-PAGE gels for Western 
blotting or quantification using SafeStain (Invitrogen). 
4.3.9  gp120 Western Blot / N- and O-linked Glycosylation / Biological Activity 
Analyses 
Analysis of the gp120 protein for vNB014 infected and control cultures was 
performed by Western blot analysis on supernatant samples, since this protein is 
secreted into the medium.  The reduced samples were run on 4-20% Tris-Glycine 
SDS-PAGE gels and blotted on nitrocellulose membranes.  The membranes were 
blocked with 5% normal donkey serum (KPL, Gaithersburg, MD) in TTBS at 4°C 
overnight, then washed with TTBS and incubated with primary antibody (1:2000)  for 
one hour at room temperature.  The primary antibody, HIV-1 gp160B Antiserum 
(HT3) in Goat (Reagent 188), was obtained  through the AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAID, NIH as well as the gp120 
standard, HIV-1 gp120 CM (Reagent 2003-CM).  The membranes were then washed 
and incubated with secondary antibody, (1:5000) Donkey Anti-Goat IgG (KPL) for   
1 h at rt.  They were then washed a final time and developed with BCIP/NBT 
Phosphatase Substrate (KPL) solution and washed in water and dried.  Scans of the 
Western blots were quantified with the Kodak EDAS system using standards of 
gp120 for comparison.   
Purified gp120 was used for analysis of the glycosylation level of the protein.  
PNGase treatment to remove N-linked glycans and a series of enzymatic reactions to 




Sigma) and the treated proteins were then run on a reducing SDS-PAGE gel and 
transferred to nitrocellulose for Western blotting as described above. 
A fusion inhibition assay was used to determine the biological activity of the 
DH12 gp120 envelope protein in the manner previously described in Hu (Hu et al. 
2000).  Briefly, 1×105 PM1 target cells (CD4+, CXCR4+, CCR5+) per well were 
incubated for 1 hour at 37°C with serial dilutions of the purified gp120 protein from 
0.3 to 30 mg/ml in duplicate wells of a 96-well plate.  The same number of Tf228 
effector cells, expressing BH10/IIIB gp160, were added to each well and the 
incubation continued at 37°C in a CO2 humidified incubator another for 3-4 hours.  
The absence of soluble envelope protein causes fusion of the two cell types and 
formation of syncytia, which can be inhibited in the presence of soluble gp120 
protein.  The degree of fusion inhibition was determined for each well, scored after 
incubation.  Plotting the degree of inhibition as a function of gp120 concentration 
allowed the determination of the 50% inhibitory dose (ID50) from the fusion-
inhibition curve (Lee et al. 1997). 
4.4  Results 
4.4.1  Seeding Cells From Microcarrier to Microcarrier 
Small-scale experiments were performed in duplicate to determine the 
feasibility of seeding cells from already growing microcarrier culture to fresh 
microcarriers.  HeLa cells were grown either in tissue culture flasks, or on 5 g/l 
Cytodex® 3 microcarriers in spinner flasks.  Cells were removed from the culture 




trypsinization inside the spinner flasks and both were seeded into new spinner flasks 
with freshly prepared microcarriers.  Figure 4-2 shows the average growth curves for 
the two types of cultures seeded.    
Regression analysis was performed for each flask independently using an 
exponential equation, VCD=VCD0 eµt, to determine the growth rate, µ, and cell 
density at seeding, VCD0.  The analysis resulted in R2 values of 1.0 and 1.0 for the 
plate seeded cultures and 0.96 and 0.97 for the microcarrier seeded cultures.  
ANOVA analysis showed no significance difference, P=0.083, between the growth 
rates for these two culture types, 0.031 and 0.025 h-1 for plate and microcarrier 
seeded, respectively.   Analysis of the intercepts, or VCD0, showed that the plate 
seeded cultures started with an average VCD of 0.025×106 cells/ml versus the 
microcarrier seeded cultures with VCD 0.071×106 cells/ml.  These values were 
statistically different with P=0.049.   
4.4.2  Growth of Anchorage Dependent HeLa Cells in a Bioreactor  
This work utilizes microcarriers in a traditional stirred tank bioreactor for 
growth of anchorage dependent HeLa cells.  To perfuse the culture, the bioreactor 
was equipped with an alternating tangential flow device (ATF) from Refine 
Technology, Co. (East Hanover, NJ)  The ATF unit is equipped with a nylon mesh 
membrane with pores of approximately 70 µm, that allows media and cell debris to 
pass through, but not microcarriers (Figure 4-3A).  The system works by alternatively 
pulling culture up into the ATF inner chamber via the movement of a diaphragm at 
the top of the unit.  The movement is controlled by alternating air and vacuum cycles. 




Figure 4-2  Seeding Method Evaluation  
Cytodex® 3 microcarriers were seeded with anchorage dependent HeLa cells 
harvested either from tissue culture plates (circles) or previous microcarrier culture 
(squares).  Exponential growth curves were fit to the average viable cell densities and 
are shown by the solid and dashed lines. 
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the center of the cylindrical mesh filter and a “fast” push of the culture back into the 
reactor to “self-clean” the mesh membrane and allow sufficient mixing with the 
contents of the reactor.  The filtrate side of the mesh membrane is connected to outlet 
tubing and a pump draws off spent medium at a controlled rate.  The time course of a 
single pressure-exhaust cycle as seen through the front sight glass of the ATF is 
shown in Figure 4-3B.  Batch growth of HeLa cells without medium exchange was 
compared to duplicate growth experiments with perfusion via the ATF, results shown 
in Figure 4-4.  Perfusing the culture extended the exponential growth phase by at least 
50 hours and lead to a higher maximum viable cell density of 4.4x106 versus 1.5×106 
cells/ml for the batch culture. 
4.4.3  Dissolved Oxygen Effect on Protein Production in Bioreactor Culture 
The dissolved oxygen level during the protein production phase was tested at 
two levels (30% and 50%), corresponding to estimates from our previous spinner 
flask study (Bleckwenn et al. 2004a). Five days after seeding, the culture (1.5 l, HeLa 
on microcarriers) was infected with vNB009 (with EGFP gene) at an MOI of 5.0 in a 
reduced volume (~0.4 l) of serum-free medium containing 1.0 mM IPTG.  After 
infection (1 h), serum was reintroduced to 10% FBS and the volume restored to 1.5 l.  
At this point the DO setpoint was either maintained at 30% or increased to 50% air 
saturation. The ATF was kept running to prevent drying of cells onto the membrane, 
but filtrate was not removed for the first day after infection.  At 24 hpi, the ATF was 
used to remove 1 l of spent medium and fresh medium with IPTG was added.  Both 




Figure 4-3  Reactor Schematic and Culture Motion with ATF™ System 
A schematic drawing of the system (Panel A) used for all bioreactor experiments is 
shown with the ATF components used for perfusion feeding.  The motion of the 
liquid culture medium is seen through the sightglass on the side of the ATF housing 
(Panel B).  The light gray seen in the back of the view above the liquid culture is the 
cylindrical mesh membrane.  As the diaphragm pulls up with vaccum, the culture 
moves up slowly into the unit in the first five panels, then quickly pushes back into 
























































Figure 4-4  Batch Versus Perfusion Growth with ATF™ System  
The viable cell densities are plotted over time for bioreactor culture grown with ATF 
for perfusion feeding (circles) or batch bioreactor culture without feeding (squares). 
 
Time (h)




























8.0±0.81 µg/106 infected cells compared to 6.0±1.5 for 30% air saturation (Figure 4-
5).  Overall, the cultures at 50% DO produced more EGFP than the cultures at 30%.  
4.4.4  Temperature Effect on Protein Production in Bioreactor Culture 
An evaluation of process temperature during the protein production phase was 
also made.  Our previous study with spinner flasks showed a dramatic increase in 
production at lower temperatures (31°C).  For the bioreactor cultures, cells were 
prepared and infected in the same manner as described previously, but after the 
infection phase, the DO was brought to 50% air saturation and the temperature was 
adjusted to 31°C.  In Figure 4-6, the maximum level of EGFP reached for the 31°C 
culture was 12±1.5 µg/106 infected cells.  Over the time course, the level of EGFP 
remained higher in the 31°C culture than the 36.5°C culture (50% DO data shown in 
Figure 4-5). 
4.4.5  Production of gp120 Protein in Bioreactor Culture 
The virus created to produce gp120 was used to infect microcarrier attached 
HeLa cells in bioreactor culture.  The growth, infection, and protein production 
conditions were chosen based on previous results with the reporter protein, EGFP.  
HeLa cells were grown on Cytodex® 3 microcarriers in a 1.5 l bioreactor utilizing the 
ATF unit for perfusion. Approximately 3×108 cells were infected with vNB014 at an 
MOI of 5.0 at ~400 ml (see above) with 1.0 mM IPTG but no serum.  After the 1 h 
infection, the conditions were reset to those of EGFP (31°C, 1.0 mM IPTG, 50% 




Figure 4-5  Effect of Dissolved Oxygen on Protein Production in Bioreactor 
Intracellular levels of EGFP are compared for bioreactor runs with the dissolved 
oxygen at 30% (circles) or 50% (squares) during the protein production phase. 
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Figure 4-6  Effect of Lowered Temperature During Protein Production in 
Bioreactor  
Intracellular levels of EGFP are shown for bioreactor runs with the temperature 
lowered to 31°C during the protein production phase. 
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Figure 4-7  gp120 Production in Microcarrier Based Reactor with ATF™ 
System  
Online parameter measurements for the reactor used to produce gp120 protein are 
shown in Panel A.  Panel B shows glucose, lactate, and viable cell density 
measurements.  Arrows indicate medium operations and infection.  Panel C shows the 
expression of gp120 over time, quantified against standards of gp120.  Western blot 












































































































































supernatant samples and the corresponding gp120 band quantification are shown in 
Figures 4-7C and 4-7D. The production run was terminated ~120 hpi when the 
controlled bioreactor parameters, pH and DO, were observed to vary significantly and 
visual inspection revealed less than 5% coverage of cells on the carriers.  The 
maximum expression level reached by this culture was 10.5 mg/l at 120 hpi, 
corresponding to 5.4 µg/106 infected cells.   
4.4.6  Purification of gp120 Protein on IMAC Column 
The gp120 was purified via IMAC column (See Methods).  Supernatant (200 
ml) collected at 96 hpi was treated with NaH2PO4 (20 mM) and NaCl (500 mM) and 
NP-40 (0.5% v/v), to inactivate any virus particles, and then was loaded onto the 
column (1 ml).  The column was washed and the protein was eluted with 10 column 
volumes of a 20 to 500 mM imidazole gradient (Figure 4-8A).  Analysis of the pooled 
fractions by reducing SDS-PAGE and Western blot with gp160 antibody are seen in 
Figure 4-8B and 4-8C.  The partially purified gp120 was concentrated for further 
analysis. 
4.4.7  Analysis of Produced and Purified gp120 Protein – Glycosylation and 
Activity 
The  purified gp120 was subjected to deglycosylation reactions with PNGase, 
to remove N-linked sugar groups, and a set of enzymatic reactions to remove the O-
linked sugar groups.  Comparing the results seen in Figure 4-9 for the purified protein 
and the standard gp120, a drop in the molecular weight of the protein upon PNGase 




Figure 4-8  Purification of gp120-6×HIS Protein from 96 hpi Culture 
Supernatant  
A280 measurements of collected fractions are shown in Panel A.  Panel B and C show 
reducing SDS-PAGE and Western blot analysis of purification samples, respectively. 
PP= Prior to purification supernatant treated with salts and NP-40 but prior to loading 
on column, FT= Flow through, W1, W2, W3= Pooled wash fractions, E1, E2= Pooled 

















































































Figure 4-9  Western Blot Analysis of Deglycosylated gp120 Samples  
Purified gp120 and gp120 standard were subjected to deglycosylation reactions then 
analyzed by Western blot. U= Undigested sample, N= PNGase treatment to remove 
N-linked glycans, N/O= Enzymatic treatment to remove both N- and O-linked 
glycans.  The two arrows at the right show the approximate locations of the full 





















Figure 4-10  Fusion-Inhibition Assay for Biological Activity of Purified gp120 
Percent cell fusion inhibition of cells expressing HIV receptors CXCR5 and CCR5 
with cells expressing HIV envelope are plotted for varying concentrations of purified 
gp120 produced from bioreactor culture.  The ID50 dose is calculated from the 





























the O-linked sugar groups does not further reduce the molecular weight.  An activity 
assay was performed to verify the function of the produced protein.  Figure 4-10 
shows the fusion-inhibition curve for the gp120 produced and purified as above.  The 
activity of gp120 (50% inhibitory dose, ID50) was calculated to be 3.1 µg/ml. 
4.5  Discussion 
The growth and infection of anchorage dependent cells in large-scale 
bioreactor cultures present some technical difficulties.  A solid support, onto which 
the anchorage dependent cells can attach, must be provided and medium 
manipulations for viral infection must be technically manageable, including complete 
exchange of medium without removing the cells, and the ability to control the 
bioreactor conditions at a lower volume during the infection phase.  This lowered 
volume has been shown to be beneficial to protein expression in plate culture 
(Bleckwenn et al. 2003).  While several systems that support these tasks are available, 
our work has focused on the stirred tank reactor with microcarriers because once the 
carriers are seeded with cells, they can be treated in largely the same manner as cells 
in suspension culture.  A few issues that arise when utilizing microcarrier cultures are 
the method of aeration, the method of cell separation for perfusion feeding, and the 
ability to achieve the proper seed train of anchorage dependent cells (Bleckwenn and 
Shiloach 2004).   
The perfusion methods currently used for suspension culture (hollow fiber, 
acoustic filter, spin filter, and inclined settler) are not suitable for microcarrrier 
culture mainly because they require pumping through tubing, which can clog and 




replace the media by allowing the microcarriers to settle at the spinner flask scale, 
this operation mode is not practical for large-scale bioreactors.  To achieve media 
separation, we implemented the ATF system which operates by transferring the cell 
covered carriers directly to the unit through stainless steel tubing.  The action of a 
diaphragm, in response to alternating vacuum and air pressure, pulls the culture to the 
ATF and pushes it back to the reactor.  The ATF houses a mesh screen filter which 
allows the passage of cell debris and medium to the filtrate line, but maintains the 
attached cells and carriers in the reactor.  Spent medium is removed at a controlled 
rate and fresh medium can be added to the reactor.  The ATF can also be used to 
retain the cells during medium exchange and volume reduction in preparation for 
infection.  This method of feeding worked well with the Cytodex® 3 microcarriers 
and HeLa cells used in our work.  It was able to handle the operations of daily feeding 
and 3× volume reduction during infection procedures without clogging or loss of 
function.  Compared to batch culture, this perfusion method increased the cell density 
at infection, thus increasing the volumetric productivity.   
It might be interesting to see whether the ATF is capable of selecting viable 
cells.  That is, it was shown for both hybridoma and CHO cell cultures that the use of 
an inclined settler could preferentially select the smaller nonviable cells for removal 
from the bioreactor (Batt et al. 1990; Searles et al. 1994). The ATF, with its mesh 
screen with pore size around 70 µm, should allow passage of any cells not attached to 
microcarriers.  Because the cells are anchorage dependent, it is likely that the most 
viable cells are attached to carriers and will be retained in the reactor, whereas, 




method.  After infection, cells will begin to detach, but are significantly larger than 
uninfected cells due to the formation of large syncytia, and we speculate that they 
might be retained in the reactor.   
Obtaining the large number of anchorage dependent cells needed for seeding a 
bioreactor becomes a significant issue as the scale increases.  For spinner flasks or 
small-scale bioreactor culture, it is possible to harvest the needed cells from multiple 
tissue culture flasks but this approach is not practical for large bioreactors.  To 
overcome this problem, researchers have previously investigated the potential of 
different cell lines to be harvested from the microcarrier and then reseeded onto fresh 
carriers (Barrett et al. 1989).  Interestingly, other researchers have found that Vero 
cells could be seeded from microcarrier to microcarrier by adding fresh microcarriers 
to a culture of confluent carriers and repeating the agitation profile, with no 
trypsinization of the cells (Wang and Fan 1999).  Upon comparison of HeLa cultures 
seeded from harvested tissue culture plates or harvested from carriers and reseeded 
onto fresh carriers, we found that there was no significant decline in growth rate or 
cell density achieved five days after seeding, when infection would occur.  The 
culture seeded from carrier culture, appeared to seed onto the carriers better, 
increasing the initial cell density and thereby maintaining a slightly higher cell 
density than the tissue culture plate seeded culture over the five days tested.  This 
phenomenon suggests a possible adaptation to attachment of the cells on the carriers 
which may be passed on to the next stage in the seed train. 
In addition to increasing cell density, our work focused on two parameters that 




in bioreactor culture can contribute to high yields of protein (Kunkel et al. 2000; Lin 
et al. 1993; Lin and Miller 1992).  Some researchers have found optimum levels of 
DO increased protein production, but that high levels decreased production due to a 
concurrent increase in proteases in the culture, (Hu and Bentley 1999; Naggie and 
Bentley 1998; Scott et al. 1992; Wang et al. 1996).  In our expression system 
increasing the DO from 30% to 50% during the protein production phase resulted in a 
higher maximum level of intracellular EGFP.  Although these results were only 
minimally different, the higher trend in expression for the 50% DO case, maintained 
throughout the course of the production phase, suggests that expression may benefit 
from increasing DO.  
Most mammalian cell lines grow best at 37°C, and significant deviations 
above this temperature are devastating to the cells (Freshney 2000).  Lower 
temperatures are tolerable, but the cells grow slower.  Interestingly, Schlaeger and 
Lundstrom (Schlaeger and Lundstrom 1998) found higher yield at lowered 
temperature (33°C) with Semliki Forest Virus (SFV) infection.  They suggested that a 
reduction in the cytopathic effects from the viral infection may increase the life of the 
cells and lead to a longer protein production phase, thereby increasing protein yield.  
In the present work, temperature was adjusted after the infection phase to ensure that 
this change had no affect on the kinetics of infection, only on protein production and 
cytopathic viral effects.  Lowering the temperature to 31°C increased specific yield 
fifty percent over the 36.5°C culture yielding about 20 mg/l intracellular EGFP.  This 
modest increase was not as dramatic as that seen in the previous study in spinner flask 




slows the process and draws out protein production over a longer period of time, with 
the maximum occurring about 75 hours after the maximum for the culture at 36.5°C.      
Once the previous experiments had lead to a defined culture process with the 
model protein, EGFP, a virus containing the gene for gp120, a secreted HIV-1 
envelope coat protein with significant post-translational modification, was used to 
infect bioreactor culture and verify the production and processing capabilities of this 
system.  Maximum expression occurred at 120 hpi with a level reaching 10.5 mg/l, 
corresponding to 5.4 µg/106 infected cells which is about double the amount seen 
previously with the vaccinia system (Barrett et al. 1989; Bleckwenn et al. 2003; Hu et 
al. 2000).  The protein was purified using an IMAC column and was treated with 
enzymes to remove N-linked or both N- and O-linked sugar groups.  The results 
revealed that the molecular weight of the protein drops to 60 kDa upon N-linked 
sugar group removal, but does not drop further on O-linked sugar group removal.  
This suggests that the majority of the glycosylation modifications are N-linked for 
this protein.  Additionally, the molecular weight of this treated protein was 
approximately the same as the theoretical amino acid weight for the protein with no 
post-translational modifications (~58 kDa).  A fusion-inhibition assay was used to 
determine the biological activity of the purified gp120 which resulted in an ID50 of 
3.1 µg/ml, similar to that seen by Hu et al (Hu et al. 2000).  This shows that the 
protein was active in binding the receptors CXCR5 and CCR5 and blocking fusion 




4.6  Conclusions 
The utility of the VOTE vaccinia virus expression system for producing 
protein in mammalian cells has been established.  Several issues relating to the 
practical operations of growing and infecting anchorage dependent cells have been 
addressed through the use of the ATF System for perfusion and medium 
manipulations, which can be scaled up through the use of larger units.  Large-scale 
considerations for seed train manipulations were evaluated and shown to be 
reasonable by the ability of these cells to be seeded from previous microcarrier 
cultures onto fresh carriers.  The controllable process parameters of dissolved oxygen 
and temperature have been studied for their effect on recombinant protein production 
during the production phase and lead to increases in protein yield, albeit more 
conditions and replicates might be warranted for locating an optimum.  
These results indicate that, with proper optimization, the vaccinia virus-HeLa 
expression system can yield high levels of recombinant protein.  The system could be 
further optimized by adjusting other process parameters such as pH or altering 
medium components.  With the basic process parameters defined, a complex protein 
of commercial interest, gp120, was then produced in bioreactor culture.  The protein 
was purified for post-translational modification and biological activity analyses, both 





CHAPTER 5:  Perfusion of Mammalian Cell Suspension 
Bioreactor Culture and Reduced Temperature During 
Production to Increase Protein Yield with the Vaccinia Virus 
Expression System4 
5.1  Summary 
Adaptation of the vaccinia virus expression system to HeLa S3 suspension 
bioreactor culture for the production of recombinant protein was conducted.  
Evaluation of a hollow fiber device for perfusion of suspension culture demonstrated 
its potential for increased cell density prior to infection and lengthened exponential 
growth phase.  The hollow fiber was also used for medium manipulations prior to 
infection.  Two process parameters, multiplicity of infection (MOI) and temperature 
during the protein production phase, were evaluated to determine their effect on 
expression of the reporter protein, EGFP.  An MOI of 1.0 was sufficient for infection 
and lead to the highest level of intracellular EGFP expression.  Reducing the 
temperature to 34°C during the protein production phase increased production of the 
protein two-fold compared to 37°C in spinner flask culture.  Scaling up the process to 
a 1.5 liter bioreactor with hollow fiber perfusion, lead to an overall production level 
of 10.44 µg EGFP/106 infected cells, or 27 mg EGFP per liter.  
                                                 
4 Bleckwenn NA, Bentley WE, Shiloach J. 2004. Perfusion of mammalian cell 
suspension bioreactor culture and reduced temperature during production to increase 




5.2  Introduction 
Vaccinia vaccinia virus infection has been described previously as a method 
to obtain small quantities of proteins in HeLa S3 cultures (Hooper et al. 1993; Jun et 
al. 1996) and as a gene delivery vector (Cooney et al. 1991; Cooney et al. 1993; 
Gomella et al. 2001; Graham et al. 1992; Hanke et al. 2002; Hanlon et al. 1998; 
McAneny et al. 1996; McClain et al. 2000; Wiktor et al. 1984; Zajac et al. 2003).  To 
begin the process of scaling up this viral expression method for the production of 
large amounts of recombinant proteins, evaluation of cell growth, infection, and 
protein production are required.   
A recombinant vaccinia virus expressing enhanced green fluorescent protein 
(EGFP) controlled by the T7 promoter based VOTE expression system (Ward et al. 
1995) was previously constructed (Bleckwenn et al. 2003).  Infection of microcarrier 
attached HeLa cells grown in spinner flasks with the recombinant vaccinia virus 
produced 2.2 µg EGFP/106 cells at infection (Bleckwenn et al. 2003).  An 
optimization of several of the infection and process parameters such as inducer 
concentration, multiplicity of infection, dissolved oxygen (DO), and temperature lead 
to an increase in the production to about 17 µg EGFP/106 infected cells in spinner 
flask cultures (Bleckwenn et al. 2004a).  Protein levels from bioreactors have been 
lower (e.g. 2-3 µg/106 cells for HIV gp160 and gp120 (Barrett et al. 1989; Hu et al. 
2000)) so we were interested in making process modifications that would increase 
this yield.    
That is, to assess the potential of this system, growth strategies implementing 




infection (MOI) and temperature were evaluated.  Medium replacement via perfusion 
can dramatically boost cell density and yield (Chen et al. 1992; Kyung et al. 1994; 
Zhang et al. 1993).  The MOI also plays an important role in expression.  
Interestingly, previous work showed that the best MOI was different for tissue flask 
and microcarrier cultures (Bleckwenn et al. 2003; Bleckwenn et al. 2004a).  This was 
not unique to vaccinia, differences between tissue plate culture and suspension culture 
were shown in baculovirus/insect cell studies (Dee and Shuler 1997a).  Further, 
lowered temperature during the protein production phase was shown to be beneficial 
for both the Semliki Forest Virus expression system (Schlaeger and Lundstrom 1998) 
and the vaccinia virus expression system in microcarrier based cultures (Bleckwenn 
et al. 2004a).  This may have been due to a reduced cytopathic effect from the virus at 
lowered temperatures, allowing the cells to remain intact and producing protein for a 
longer period of time, although this was not shown.   
Several methods are available for perfusion of suspension culture including 
hollow fiber, spin filter, and acoustic filter (Bleckwenn and Shiloach 2004).  The 
present viral expression method requires that the cell separation device enable rapid 
medium exchanges, such as during the infection process when the serum 
concentration and volume are reduced creating a more effective infection 
environment.  The hollow fiber system is relatively simple, requiring only a filter 
cartridge, tubing, and peristaltic pumps.  Hollow fiber cartridges have been 
successfully used by other laboratories for perfusion of mammalian cell cultures 




exchange if sized properly.  This work describes scale-up evaluation of the HeLa S3-
vaccinia protein expression method in a hollow fiber perfusion culture. 
5.3  Materials and Methods 
5.3 1  Cell Maintenance and Expansion 
HeLa S3 cells (ATCC CCL-2.2) were maintained in 200 ml spinner flasks in 
Dulbecco’s Modified Eagle’s Medium (DMEM, Biosource, Camarillo, CA) with 4.5 
g/l glucose, without calcium, supplemented with 4 mM glutamine (Invitrogen, 
Carlsabd, CA) and 10% fetal bovine serum (FBS, Biosource).  The cultures were 
passaged every 3-4 days, reducing the cell density to approximately 2×105 cell/ml 
while retaining at least 10-20% conditioned medium in the new culture.  Cultures 
were expanded into multiple 1000 ml spinner flasks to obtain the number of cells 
needed for seeding bioreactor cultures.   
5.3.2  Cell Density and Viability Measurements 
Samples of cell suspension were taken from cultures and a portion diluted in 
PBS and mixed with 0.4% trypan blue solution (Sigma, St. Louis, MO) for viability 
staining.  The stained solution was then counted using a hemacytometer to determine 
total cell density and viability. 
5.3.3  Metabolite Measurements 
Glucose and lactate measurements were made on supernatant samples from 
spinner flask or bioreactor cultures using a YSI 2700 Biochemistry Analyzer (Yellow 




5.3.4  Spinner Flask Seeding and Growth 
Spinner flask cultures containing 200 ml of culture in 250 ml Bellco spinner 
flasks with stir bar and paddle (Bellco Glass, Inc., Vineland, NJ) were seeded with 
1.0×105 cell/ml.  Agitation speed was set at 50 rpm in a 5% CO2, humidified, 37°C 
incubator.  Cultures were monitored daily for cell density, viability, glucose and 
lactate.   
5.3.5  Suspension Bioreactor Seeding and Growth 
HeLa S3 cells were seeded into a 2.2 l bioreactor (New Brunskwick Scientific, 
New Brunswick, NJ) with a working volume of 1.5 l using the same medium as was 
used for spinner flask culture with the addition of 100 units/ml Penicillin and 100 
µg/ml Streptomycin (Invitrogen) to reduce the chance of contamination.  
Approximately 10-20% of the final reactor volume was conditioned culture medium 
from the seeding spinner flasks to ensure growth of the culture.  Cells were seeded to 
a density of 2×105 cell/ml and grown at 36.5°C, 30% DO based on air saturation at 
36.5°C, and pH 7.2.  Perfusion feeding was achieved for this culture by using a 
hollow fiber cartridge (A/G Technology Corp., Needham, MA) with 0.45 µm pores 
and 1.0 mm inner diameter capillaries through which the culture flowed.  Culture was 
circulated at a rate of about 15 reactor volumes per day and medium exchanged up to 
1.5 reactor volumes per day via level controlled addition of fresh feed.  Aeration was 
achieved through headspace gassing at 1.0 l/min until day 3-4 when the aeration was 
switched to sparging into the culture at 0.3 l/min and 0.1% Pluronic F-68 was added 
to reduce foaming and shear effects.  A schematic of the reactor setup is shown in 




Figure 5-1  Suspension Bioreactor Schematic with Hollow Fiber Unit for 
Perfusion  
A schematic diagram of the cell suspension based bioreactor with the hollow fiber 




























perfusion unit.  Samples were taken daily to determine cell density, viability, and 
glucose and lactate concentrations.   
5.3.6  Virus Preparation 
Virus containing the gene for EGFP, vNB009, was constructed as described 
previously (Bleckwenn et al. 2003).  A portion of the viral stock was incubated 1:1 
with 1× trypsin at 37°C for 30 minutes with vigorous vortexing every 10 minutes, to 
break up clumps.  This preparation was then used to infect spinner flask or bioreactor 
culture at the appropriate MOI. 
5.3.7  Infection 
Spinner flask cultures of HeLa S3 cells in exponential phase were mixed to 
obtain a uniform population for infection experiments.  20×106 cells were centrifuged 
at 300×g for 5 minutes for each experimental condition.  Cells were resuspended in 
approximately 20 ml of their conditioned medium.  They were transferred to fresh 
Bellco 250 ml spinner flasks with stir bar and paddle.  Medium was brought to 70 ml 
with serum-free medium and inducer was added to 1.0 mM IPTG.  Virus vNB009 
was added to infect at the appropriate MOI and the flasks were returned to the 
incubator for one hour of infection.  Medium was then brought up to 200ml with 10% 
FBS and 1.0 mM IPTG.  The cultures were incubated and samples taken daily for cell 
count, viability, glucose, lactate, and protein determination.  Feeding was performed 
to keep glucose above 1.0 g/l and lactate below 2.0 g/l at either 24 hpi or both 24 and 




aspirating the medium and resuspending them in fresh medium with IPTG.  This 
mixture was then returned to the spinner flask and the culture incubated.   
5.3.8  Production in Bioreactors 
Five days after seeding 2×105 cell/ml into the bioreactor, viable cell density 
measurement was made on the culture to determine the total number of cells.  
Medium without serum or Pluronic F-68 but containing 1.0 mM IPTG was connected 
to the reactor through the feed addition pump.  A hollow fiber cartridge was used to 
perform exchange of the culture supernatant to this serum-free induction medium and 
to reduce the volume in the reactor to about 400 ml.  This exchange and reduction 
process took about five hours to perform.  Trypsinized virus vNB009 was diluted in 
100 ml of serum-free medium and added to the reactor to infect at an MOI of 1.0.  
The infection phase lasted one hour in this reduced serum and volume environment, 
after which the medium volume was brought back to 1.5 liters and serum and 
Pluronic F-68 reintroduced to 10% and 0.1%, respectively.  The temperature and DO 
setpoints were also adjusted at this time to either 34°C or 36.5°C and 50%, 
respectively.  The culture was gradually fed using the hollow fiber for exchange and 
level control for addition of one liter of media between 24 and 48 hpi.  Samples were 
taken periodically and analyzed for glucose, lactate, cell density, viability, and 




5.4  Results 
5.4.1  Effect of MOI on EGFP Production with Suspension HeLa S3 Cells 
As noted earlier, the effects of MOI might change depending on scale and 
reactor configuration.  Here, we first evaluated the MOI in spinner flasks.  Spinner 
flask cultures with suspension HeLa S3 were used to determine the effect of MOI on 
the recombinant protein yield.  Cultures (200 ml) were infected with vaccinia virus 
carrying the EGFP reporter gene, vNB009, at MOI 0.0, 1.0, 5.0, and 10.0 pfu/cell.  
The resulting intracellular EGFP expression values are shown in Figure 5-2A.  MOI 
1.0 had the highest expression level at 1.6±0.11 µg/106 infected cells occurring ~44 
hpi.  This value was statistically higher than that for MOI 10.0, P=0.017, but not MOI 
5, P=0.053, where both MOI 5.0 and 10.0 had maximums occurring ~14 hpi earlier 
than MOI 1.0.  Viable cell densities measured at 24 and 48 hpi are shown in Figure 5-
2B, showing slightly higher cell densities at 24 and 48 hpi for MOI 1.0 as compared 
to  MOI 5.0 or 10.0, although these were not statistically different, P≥0.084.  In all 
three cases, the intracellular EGFP levels drop after reaching their maximums. 
5.4.2  Effect of Temperature on EGFP Expression in HeLa S3 Suspension Culture 
Lowering the culture temperature in a viral expression system may increase 
the protein yield.  Here, we evaluate temperature reduction in spinner flask cultures 
containing 106 HeLa S3 cells/ml infected at an MOI of 1.0 with the recombinant virus 
carrying the EGFP reporter gene. After infection, the flasks were incubated at 25, 28, 
31, 34, and 37°C±0.5°C (37°C culture results were from previous MOI experiment at 




Figure 5-2  Effect of Multiplicity of Infection on Production in Spinner Flask 
Cultures 
The intracellular EGFP levels are shown in Panel A for MOI = 0 (circle), 1.0 
(square), 5.0 (triangle), and 10.0 (diamond).  The viable cell densities at 24 and 48 hpi 
are shown in Panel B for MOI = 0 (black), 1.0 (medium gray), 5.0 (dark gray), and 







































































shown in Figure 5-3A.  Maximum EGFP levels were seen with 34°C at 44 hpi, 31°C 
at 52 hpi, and 28°C at 96 hpi.  The EGFP levels achieved were 3.28 ± 0.080, 2.57 ± 
0.36, and 3.4 ± 0.29 µg/106 infected cells, respectively, all within error of each other, 
P≥0.057.  All three of these temperatures resulted in maximum EGFP levels above 
37°C and 25°C with statistical significance, P≤0.0065.  The percent viability is 
plotted in Figure 5-3B which shows that 25°C and 28°C maintain higher cell 
viabilities than temperatures above 30°C.     
5.4.3  Perfusion Growth of HeLa S3 Suspension Cells 
The growth profile of HeLa S3 suspension cells was determined by growing 
the cells using perfusion mode in a bioreactor equipped with a hollow fiber 
membrane cartridge. The total cells density and the percent viability are shown in 
Figure 5-4.  Exponential growth of the HeLa S3 cells was maintained for about seven 
days in this system with a maximum viable cell density of 1.3×107 cells/ml. 
5.4.4  Production of EGFP in HeLa S3 Suspension Bioreactor with Hollow Fiber 
Perfusion 
EGFP was produced in perfused HeLa S3 bioreactor culture under the 
conditions determined above for the MOI and temperature and compared to a single 
production run at 36.5°C.  The results for the runs at 34°C are shown in Figures 5-5A 
to 5-5D and the comparison of expression in Figure 5-6.  Infection was performed in 
the bioreactor at a cell concentration of 2.9 ± 0.37×106 cell/ml, using an MOI of 1.0, 
and adjusting the temperature during production to either 34°C or 36.5°C.  Figures 5-




Figure 5-3  Effect of Temperature on Production in Spinner Flask Cultures 
The intracellular EGFP levels are shown in Panel A and viabilities in Panel B for 
temperatures during the production phase of 37°C (square, data from Figure 5-2A), 
34°C (circle), 31°C (downward pointing triangle), 28°C (diamond), and 25°C 




























































Figure 5-4  Growth of HeLa S3 Cells in Suspension Bioreactor Culture with 
Hollow Fiber Perfusion Device 
Total cell density (circle) and percent viability (square) are shown over the course of 
a single bioreactor run growing HeLa S3 suspension cells while utilizing a hollow 
fiber cartridge for perfusion of the culture. Error in measurement is less than 12% for 
total cell density, except for one anomalous measurement at 189 hours with 27%, and 












































parameters for a typical production run in 5-5A, the average glucose and lactate 
values in 5-5B and the average total cell density and percent viability in 5-5C.  
Intracellular and extracellular levels of EGFP are shown in Figure 5-6 for both 
temperatures.  The maximum intracellular EGFP was achieved for the production run 
at 34°C, ~120 hpi at 10.44 ± 0.018 µg/106 infected cells.  This corresponds to 27 
mg/l, which is higher than the level obtained at 36.5°C (at 3.5 µg/106 infected cells).  
In both cases, the intracellular level of EGFP drops after reaching the maximum 
value, and the extracellular concentration increases over time. 
5.5  Discussion 
Vaccinia virus infection of HeLa S3 cells has been used to produce small 
quantities of proteins in spinner flask cultures (Hooper et al. 1993; Jun et al. 1996).  
Scale-up of the process for production in bioreactor culture requires an examination 
of critical process parameters such as multiplicity of infection, temperature, and cell 
density.  Multiplicity of infection, in other viral systems, has been shown to affect 
protein yield (Blasey et al. 1997; Gotoh et al. 2002; Hu and Bentley 2001).  In this 
work, the optimum MOI was found to be 1.0, indicating that only one infectious virus 
particle was needed per cell to achieve maximum expression.  This is less than the 
MOI of 5.0 that was found optimum for the anchorage dependent HeLa cell line in 
microcarrier based culture (Bleckwenn et al. 2004a).  The infection kinetics are 
certainly different for the cell suspension based system than in the microcarrier based 
system.  A similar phenomenon was described previously for baculovirus infection 
where suspension cultures had higher attachment rates for the virus than monolayer 




Figure 5-5  Production Run at 34°C 
The online parameters measured through the data acquisition program are plotted in 
Panel A for a typical run from seeding, through infection, to harvest, with arrows 
showing the onset of infection and initiation of feeding after infection.  Average 
glucose (circle) and lactate (square) values are shown in Panel B over the course of 
the two production runs.  Average total cell density (circle) and percent viability 





































































































































Figure 5-6  Production of EGFP in HeLa S3 Suspension Bioreactor  
Average intracellular (circle with solid line) and extracellular (circle with dashed line) 
levels of EGFP for the average of two production runs at 34°C and intracellular 
(square with solid line) and extracellular (square with dashed line) levels of EGFP for 
a single production run at 36.5°C are shown.
Time (hpi)





























that the infection in the vaccinia infected suspension system might be less efficient 
than the microcarrier based system because, in order to maintain cell health, a portion 
of conditioned medium containing serum was carried over into the infection medium.  
Previous results with the anchorage dependent HeLa cells showed that the removal of 
serum during infection lead to the highest level of expression (Bleckwenn et al. 
2003).  However, it appeared that the level of serum was reduced sufficiently enough 
to not interfere with infection, which agreed with the results of Bleckwenn that a low 
level of serum, 2.5%, did not dramatically lower the expression.  In the present 
system, MOIs of 5.0 and 10.0 appeared to increase cell death over MOI 1.0, as 
indicated by the lower viable cell densities reported at 24 and 48 hpi, but these results 
were not shown to be statistically significant.  This lower viable cell density may 
partially explain the lower expression at these higher MOI, due to a smaller number 
of cells available for protein production.  
Several researchers have modeled virus systems to gain an understanding 
about the limiting factors for viral infection processes.  Dee et al (Dee and Shuler 
1997a) developed a model for baculovirus infected insect cells which could be 
generalized to other acid-dependent enveloped viruses.  They found that binding of 
the virus to the cell receptor was the rate limiting step.  Chilakuru modeled the 
infection of vaccinia virus, finding that the ionic composition of the medium and 
presence of serum proteins played an important role in adsorption kinetics and cells 
infected during exponential phase yielded more virus particles than those infected in 
lag or stationary phase (Chillakuru et al. 1991).  These results suggest that other 




amount of virus binding.  They also support our goal of increasing infection 
efficiency by obtaining a high density of cells in exponential growth phase prior to 
infection.   
Lowering culture temperature in viral systems can lower the cytopathic effect 
and increase protein yield.  Temperatures of 34°C, in the Semliki Forest Virus (SFV) 
system, (Schlaeger and Lundstrom 1998) and 31°C, in the microcarrier based 
vaccinia system (Bleckwenn et al. 2004a) increased protein production compared to 
37°C cultures.  In the HeLa S3 suspension cells it was found that cultures grown at 
28°C after infection produced the largest amount of intracellular EGFP, within error 
of 31°C and 34°C, but because this level of production was reached much later, a 
temperature of 34°C after the infection phase was used for further experiments.  The 
viability of the cultures over time decreased more rapidly for temperatures above 
30°C than for those below, indicating decreased cytopathic effect at lower 
temperatures, leading to slower cell death.  The experiments performed in spinner 
flasks where the cultures were incubated at lower temperatures not only affected the 
temperature of the culture, but also the level of dissolved gases such as oxygen and 
carbon dioxide, thereby, potentially changing the culture pH.  Without isolating 
temperature as the only changed parameter, it is likely that the results obtained from 
these spinner flasks were not due to temperature alone.   
  Of particular importance to a viral infection system is the achievement of high 
cell density of exponentially growing cells, which will very likely increase the 
volumetric productivity. It is particularly important to have healthy, exponentially 




hollow fiber perfusion method was implemented to generate high cell density cultures 
and to perform the media replacement and volume reduction needed for efficient 
infection.  The maximum viable cell density reached for HeLa S3 cells grown in a 
bioreactor, with a hollow fiber cartridge used for perfusion, was 1.3×107 cell/ml, 
several times higher than what was achieved in batch spinner flask culture.  This 
increase in maximum cell density was also accompanied by an exponential growth 
phase of about seven days.  The growth profile provided a timeframe in which to 
infect the cells from approximately 100-175 h post seeding.  The medium 
manipulations required just prior to infection, to reduce the serum concentration and 
lower the volume in the reactor while maintaining the total number of cells, was 
easily performed with the hollow fiber and could be scaled up with larger hollow 
fiber units as the size of the bioreactor increases.   
EGFP reporter protein was produced in 1.5 liter bioreactor culture using the 
conditions defined by the spinner flask infection experiments and the growth profile 
of HeLa S3 using hollow fiber perfusion feeding.  The expression results indicate that 
the production of EGFP in this perfusion based suspension system attained 10.44 ± 
0.018 µg/106 infected cells.  This was three times the level seen when the production 
temperature was maintained at 36.5°C.  It is also important to notice that the 
maximum level of expression for the bioreactor system occurred about 50-60 hours 
later than the spinner culture at the same temperature, possibly due to controlled 
environment and the cells’ physiological state.  The dramatic increase in production 




separately from dissolved gases, indicated that temperature plays a significant role in 
protein yield with this expression method. 
5.6  Conclusions 
The Hela S3-vaccinia virus expression system has been used for research 
purposes to make small quantities of proteins.  Through an investigation of some key 
parameters and evaluation of a hollow fiber perfusion method in order to increase cell 
density, the production capacity of this expression method was increased to the 
bioreactor scale at 1.5 liters, and theoretically could be scaled further with increased 
reactor and hollow fiber cartridge size.  This system could be further optimized for 
production purposes by altering other process parameters such as pH or altering 
medium components.  These results provide a starting point for further process 




CHAPTER 6:  Comparison of Protein Expression in Multiple 
Mammalian Cell Lines Utilizing the Vaccinia Virus Expression 
System5 
6.1  Summary 
Production of recombinant proteins with the vaccinia virus expression system 
in five mammalian cell lines (HeLa, BS-C-1, Vero, MRC-5, and 293) was 
investigated for protein yield and proper post-translational modifications.  Regulatory 
acceptance of the host cell line was taken into consideration, as well as relevant 
process knowledge for ease of scale-up with the particular cell type.  Two proteins 
were expressed, enhanced green fluorescent protein (EGFP) in the cytoplasm, and 
gp120 secreted into the culture medium.  Because gp120 contained a significant 
amount of post-translational modification, this protein, produced by the different cell 
lines, was further analyzed by PNGase digestion for N-linked glycosylation 
modifications.  HeLa cells produced the most EGFP at 17.2 µg/well with BS-C-1 and 
293 following.  BS-C-1 produced the most gp120 at 28.2 µg/ml with 293 and Vero 
following.  MRC-5 had a very high productivity on a per cell basis, but low cell 
density and slow growth rate made the overall production low.  Based on these results 
and overall process considerations, 293 cells are recommended for further production 
process optimization in a serum-free suspension system. 
                                                 
5 Bleckwenn NA, Bentley WE, Shiloach J. 2004. Comparison of protein expression in 





6.2  Introduction 
The vaccinia virus expression system has been used to produce protein with 
HeLa (Bleckwenn et al. 2003; Bleckwenn et al. 2004a; Hu et al. 2000) and HeLa S3 
(Jun et al. 1996) cells.  Although these results were promising for a manufacturing 
process based on vaccinia virus infection, concern remained that HeLa cells, and the 
HeLa S3 suspension line derived from them, were inappropriate for manufacture of 
therapeutic proteins.  These cells were originally isolated from a human cervical 
adenocarcinoma (Gey et al. 1952; Jones et al. 1971) and are known to cause cancer 
when injected into mice.  Other researchers produced protein using vaccinia virus 
with Vero cells attached to microcarriers in 40 l culture (Barrett et al. 1989), but only 
at ~2-3 µg gp160/106 cells.  Because of this low level of expression and concerns 
about HeLa as host cells, we carried out an investigation of other cell lines, evaluating 
protein production capability, including several that might be more acceptable to the 
regulatory authorities as a production cell line using the vaccinia expression system.     
The HeLa cell line used in previous work was used as a point of comparison.  
By testing this line under the same conditions as the others, it was possible to make 
direct comparisons between the cell lines at the chosen conditions of infection and 
expression.  This was important because some work had already been done to 
optimize the HeLa cell system with vaccinia, indicating that optimization with each 
cell line could improve production.  The cells chosen for comparison were BS-C-1, 
MRC-5, Vero and 293.  BS-C-1 cells have been used extensively with vaccinia virus 
in plaque assays in order to make titer determinations because they form tight 




(Moss and Earl 2000).  The cells originated from African green monkey kidney cells 
(Hopps 1963) and their historical use with vaccinia virus suggests they may be useful 
as a point of comparison to more appropriate cell lines for the purpose of recombinant 
protein production.  
MRC-5 cells are currently used by BioReliance Corp. (Rockville, MD) in the 
manufacture of clinical, and potentially commercial, supplies of vaccinia virus for a 
Smallpox vaccine.  This cell line was derived from human lung fibroblasts (Jacobs et 
al. 1970). The cells are anchorage dependent, but have a fairly slow growth rate.  Due 
to the established manufacturing process with these cells for vaccine production, they 
have already been through some of the regulatory hurdles of the approval process.  
Vero cells are also an anchorage dependent cell line, like BS-C-1.  They 
originated from African green monkey kidney cells (Yasumura and Kawakita 1962) 
and were used previously by Barrett (Barrett et al. 1989) to produce HIV-1 gp160 in a 
40 liter microcarrier based bioreactor utilizing vaccinia virus.  These cells are fairly 
easily grown and have a faster growth rate than MRC-5 cells (bi-weekly split ratio 1:3 
to 1:6 versus 1:2 to 1:5 recommended by ATCC Rockville, MD).  They have already 
been shown to produce recombinant proteins via vaccinia virus.  Also, the limited 
culture life of these cells, compared to continuous cell lines, makes them appealing 
for use in commercial manufacturing processes due to the reduced level of concern 
over cancer causing components from the host cell passing along to the final product.  
Hence, Vero cells were also tested. 
 293 cells were derived from human embryonic kidney cells (Graham et al. 




production.  These cells have been used for clinical production of biologic products 
(Farson et al. 1999; Habib et al. 1999) which makes them desirable due to their 
history of use in clinical evaluation.  Additionally, there are several commercially 
available media for adaptation of these cells to serum-free suspension growth.  
Utilizing a defined serum-free medium makes this cell line amenable to large-scale 
production. 
Previous surveys of cell lines for recombinant protein production using 
another virus-mediated expression system have proven successful in that cell lines 
with superior glycosylation characteristics, growth rate, and product yield have been 
found (Davis et al. 1993; Hink et al. 1991; Rhiel et al. 1997; Wickham et al. 1992; 
Zhang et al. 2002a; Zhang et al. 2002b).  We tested protein production of two 
proteins, enhanced green fluorescent protein (EGFP), which is expressed in the 
cytoplasm, and the HIV-1 envelope coat glycoprotein, gp120, which is secreted into 
the culture medium and contains a significant amount of N-linked glycans.  In 
summary, this article describes a production comparison of EGFP and gp120 in the 
HeLa, BS-C-1, Vero, MRC-5 and 293 cell lines using the vaccinia virus expression 
system.  
6.3  Materials and Methods 
6.3.1  Cell Line Growth and Maintenance 
HeLa (ATCC CCL-2), BS-C-1 (ATCC CCL-26), Vero (ATCC CCL-81), 
MRC-5 (ATCC CCL-171), and 293 (ATCC CRL-1573) were all grown in 




supplemented with 10% fetal bovine serum (FBS) in 75-cm2 tissue culture flasks and 
passaged every 3-4 days.   Vero cells were used within 25 passages, MRC-5 within 
12 passages, and 293 within 25 passages of thawing for experiments. 
6.3.2  Virus Preparation 
Viruses vNB009, producing EGFP, and vNB014, producing gp120, were 
constructed as described previously (Bleckwenn et al. 2003; Bleckwenn et al. 2004b).  
Purified viral stocks were used for all experiments where a portion of the stock was 
incubated with an equivalent volume of 1× trypsin to separate clumps.  This mixture 
was incubated at 37°C for 30 minutes with vigorous vortexing every 10 minutes.  The 
trypsinized stock was then diluted and used to infect cultures at the appropriate 
multiplicity of infection (MOI). 
6.3.3  6-Well Plate Infection and Expression 
Wells of 6-well plates were seeded 2-3 days prior to use in experiments at 
densities which would result in wells just prior to confluent for experiment.  They 
were grown in DMEM+10% FBS.  For infection, one 6-well plate for each cell line 
was sacrificed for cell count determination.  Six wells were prepared, with cells 
removed and resuspended, to determine the number of cells per well.  Specifically, 
the densities used for infection were HeLa at 1.6×106, BS-C-1 at 3.4×106, Vero at 
8.3×105, MRC-5 at 1.7×105, and 293 at 1.2×106cells/well.  The remaining plates were 
then used for infection and assumed to have the same cell densities for each cell line.  
The cells were washed with DMEM without serum and either infected for 1 hour in 




infected.  Plates were sacrificed for samples at 24, 48, and 72 hpi.  Two wells with 
each virus or uninfected control were harvested at each timepoint.  Cells were scraped 
using the plunger of a 1 cc syringe.  The medium and cells were collected and 
centrifuged for 5 minutes at 1000×g.  Supernatant medium was removed to a separate 
tube and both pellet and medium samples were saved for each well.   
Pictures of cells for each condition were taken with a microscope using 100× 
magnification and a Kodak MDS90 documentation system.  Additionally, 
fluorescence photography of the vNB009 infected cells was also performed using a 
FITC filter.   
6.3.4  EGFP Analysis 
Analysis of EGFP expression in the vNB009 and mock infected cells was 
performed by resuspending the cell pellets for those samples in lysis buffer (100 mM 
Tris pH 7.4, with 1× Complete protease inhibitor (Boehringer Mannheim GmbH, 
Germany) and 0.5% Triton X-100) and incubating for 30 minutes at 37°C.  
Fluorescence intensity was measured on 100 µl samples in 96-well optically black 
plates using a fluorescence spectrophotometer with excitation 485 nm and emission 
512 nm with an auto cutoff filter at 495nm.   Samples of supernatant were compared 
against standards of rEGFP in medium to determine extracellular EGFP.  Readings 
from the lysed pellet samples were compared against standards of recombinant EGFP 




6.3.5  gp120 Analysis 
Analysis of the gp120 protein was performed by Western blot after running 
samples on reducing SDS-PAGE gels.  Primary antibody, HIV-1 gp160B Antiserum 
(HT3) in Goat (Reagent 188), from DAIDS, NIAID, NIH produced under contract by 
Repligen, was obtained  through the AIDS Research and Reference Reagent Program, 
Division of AIDS, NIAID, NIH as well as the gp120 standard, HIV-1 gp120 CM 
(Reagent 2003-CM), used in the Western blots.  Scans of the Western blots were 
quantified with Kodak EDAS system   
6.3.6  gp120 Purification and N-linked Glycan Analysis 
Culture supernatants were collected and purified using a Ni-NTA spin 
purification kit (Qiagen).  Briefly, a 10× salt and NP-40 solution was added to the 
supernatants to a final concentration of 0.5% NP-40, 50 mM NaH2PO4 and 300 mM 
NaCl, mixed and incubated overnight at 4°C to inactivate virus.  Imidazole was added 
to 10 mM and the pH adjusted to 8.0.  The Ni-NTA resin column was equilibrated 
with lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) and 
two aliquots of 500 µl supernatant were cycled through the column twice to bind the 
protein, centrifuged at 100×g for 2 minutes each time.  The column was washed four 
times with 600 µl wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 
pH 8.0).  The protein was then eluted for each sample in two 100 µl fractions with 
elution buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM Imidazole, pH 8.0), 
centrifuging at 100×g for 1 minute each time.  The two elutions for each cell line 
supernatant were combined and concentrated (Microcon YM-10, 10 kDa cutoff, 5 




µl) were then dialyzed (Amika Dispo-Biodialyzer) into 10 mM Tris at pH 7.0.  
Deglycosylation reactions were performed with PNGase F (Sigma E-DEGLY) in pH 
7.0 buffer for 24 hours at 37°C.  Portions of these reactions were used as samples for 
reducing SDS-PAGE gel and Western blot analysis.  
6.4  Results 
6.4.1  Comparison of EGFP Production in Five Cell Lines 
Six-well plate cultures of HeLa, BS-C-1, Vero, MRC-5, and 293 cells were 
infected with vNB009 vaccinia virus, containing the gene for EGFP, at an MOI of 1.0 
and induced (1.0 mM IPTG) to express EGFP.  Cell pellets were analyzed for EGFP 
expression (Figure 6-1).  The HeLa cell line expressed more EGFP on a per cell basis 
(Figure 6-1A), 10.9 µg/106 infected cells, and overall (Figure 6-1B), reaching 17.2 
µg/well, than any of the other lines tested.  On a per cell basis, MRC-5 cells reached 
about half the specific production as the HeLa cells but because the cell density was 
lower, due to their larger size and slower growth rate, the overall production was low.  
BS-C-1 cells produced 2.6× less EGFP/ml and the 293 about 8× less than HeLa 
(Figure 6-1B).  Visualization of the cells was performed using standard light and 
fluorescence microscopy and images are shown in Figure 6-2.  Evident in these 
photos are the extent of infection between the various cell lines and the relative EGFP 
expression levels.  All the cell lines showed approximately the same degree of 
cytopathic effect from the viral infection, based on the rounding appearance and 
detachment from the culture plates.  Note the apparent differences in the protein 




Figure 6-1   EGFP Expression in Five Cell Lines 
Intracellular EGFP expression profiles are shown for the five cell lines tested: HeLa 
(circle), BS-C-1 (square), Vero (upward pointing triangle), MRC-5 (downward 
pointing triangle), and 293 (diamond).  Results are presented on a per cell basis, Panel 



































































Figure 6-2  Microscopic Images of Cell Lines 
Pictures of the various cells lines are shown infected with EGFP or gp120 producing 
virus, or mock infected under 100× magnification at 24, 48, and 72 hpi.  Fluorescence 
images are shown for EGFP expressing cultures only because this protein is only 





































6.4.2  Comparison of gp120 Production in Five Cell Lines 
The infection protocol used for EGFP production was also performed with all 
five cell lines using vaccinia virus vNB014 to produce gp120 protein.  The gp120 
production was followed by Western blot analysis (as opposed to EGFP 
fluorescence).  Figure 6-3 shows the quantified Western results on a per cell basis 
(Panel A), and the overall production (Panel B).  On a per cell basis, MRC-5 cells 
outperformed the others, reaching 142 µg/106 infected cells, but as before, due to the 
lower cell density and slow growth rate they did not perform as well on an overall 
basis.  Vero and 293 cells were next with 2 to 3-fold less gp120.  The overall 
production results showed that BS-C-1 was superior at 28.2 µg/ml (19.9 µg/ml 293, 
16.8 µg/ml Vero, 9.75 µg/ml MRC-5, and 6.76 µg/ml HeLa). 
6.4.3  Initial gp120 Glycan Analysis 
Figure 6-4A depicts a Western blot comparison of each of these cell lines at 
72 hpi.  There was a difference in the appearance of the bands, where 293 and Vero 
produced gp120 with slightly sharper bands than the other cell lines.  Purified gp120 
from all five cell lines was subjected to PNGase F treatment to remove the N-linked 
glycans from the protein.  Previous results in HeLa cells revealed the N-linked 
glycans contributed about half the molecular weight of the protein (Hu et al. 2000).  
SDS-PAGE and Western blot analysis of the results of these digestions are shown in 
Figure 6-4B.  The PNGase treatment trimmed the proteins down to approximately 60 
kDa.  Note, the PNGase F digested bands appeared significantly sharper than the 




Figure 6-3  gp120 Expression in Five Cell Lines  
Secreted gp120 expression profiles are shown for the five cell lines tested: 
HeLa (circle), BS-C-1 (square), Vero (upward pointing triangle), MRC-5 (downward 
pointing triangle), and 293 (diamond).  Results are presented on a per cell basis, Panel 























































Figure 6-4  Western Blot Analysis of gp120 Production at 72 hpi 
Western blot analysis is shown in Panel A for  the 72 hpi supernatant samples from 
cultures infected with virus expressing gp120 protein (+) for each cell line, next to 
supernatants from cultures infected with virus expressing EGFP (-), as negative 
controls. The left most lane shows gp120 standard.  Western blot analysis is shown in 
Panel B for the concentrated, purified, supernatant samples taken at 72 hpi from 
cultures infected with virus expressing gp120 protein for each cell line.  Each sample 
is either untreated (U) or treated with PNGase (P) to remove N-linked glycans from 
the protein.  gp120 standard, untreated and treated, is shown in the left most lanes.   
The upper arrow on the right indicates the position of the undigested protein, whereas 





































































Note, microscopy images of the infected cells are also shown in Figure 6-2.  
The degree of cytopathic effect (as evident by cell rounding and detachment from the 
culture plate) from this virus among the cell lines was roughly equivalent, and 
showed approximately the same level of infection, similar to the results of EGFP. 
6.5  Discussion 
Production of recombinant proteins with the vaccinia virus expression system 
is advantageous because multiple cell lines can be screened for levels of expression 
and proper post-translational modifications without having to generate multiple 
recombinant cell lines.  Additionally, vaccinia virus may be able to produce very 
large proteins (the genome is fairly large, 200,000 bp).  That is, other researchers 
have speculated that vaccinia can accommodate an insert up to 25,000 bp without 
hindering the viral and protein production processes (Smith and Moss 1983).   
Our results have demonstrated that vaccinia can produce  both intracellular 
and secreted proteins in several cell lines, some of which have been used for clinical 
production processes.  Interestingly, our results (which were not optimized) revealed 
that peak production was not consistent under these conditions, BS-C-1 cells were 
best in terms of gp120 but HeLa were best for EGFP.  This may be due, in part, to the 
location of expression, (e.g. EGFP was produced intracellularly and gp120 was 
secreted).  Also, because EGFP does not require post-translational modifications, 
protein expression is not limited by these processing pathways.   
Differences in protein structure via varying glycosylation patterns were also revealed 




digestion.  The tightness is affected either by the heterogeneity of the amino acid 
sequence as a result of truncation or because of heterogeneity of post-translational 
modifications.  The protein bands appear to span a molecular weight range of about 
90 to 120 kDa.  If the width of the expression bands were caused by truncation of the 
amino acid structure of the protein, the bands would also appear with a range 
covering 50 kDa upon deglycosylation analysis.  But upon treatment with PNGase, 
the width of the bands drops to only about a 10 kDa span at 60 kDa molecular weight, 
which is close to the theoretical molecular weight calculated for the amino acid 
sequence without any post-translational processing of 58 kDa.  This suggests 
heterogeneity in the glycosylation patterns of the gp120 produced by these cell lines.  
Although defined and consistent heterogeneities of glycosylation structure are 
somewhat expected and may be accepted in production processes, often, only one 
particular structure is the active form. It is desirable to produce only the active form 
in order to increase potency of the compound and reduce dosage.      
6.6  Conclusions 
In summary, the vaccinia virus expression system has been shown to produce 
both intracellular and secreted proteins in various cell lines.  Complex post-
translational modifications were compared among the cell lines tested and could 
further be evaluated in other mammalian cell lines.  The results from overall 
expression of both gp120 and EGFP, as well as other process considerations, 
suggested that investigation and optimization of a 293 based process, where the host 
cells could be adapted to serum-free suspension growth, was warranted for further 




CHAPTER 7:  Conclusions and Future Directions 
7.1  Concluding Remarks 
The vaccinia virus expression system offers a method of recombinant protein 
production for complex proteins of significant size.  The work presented here has 
evaluated several aspects of the infection and production process and the ability to 
scale these up to bioreactor culture.  The overall objective to develop a recombinant 
protein production process was achieved, but has left room for further improvements.  
The work was performed with incremental improvements to the understanding of the 
process and the overall results of what was discovered follows. 
Chapter 2 focused on the construction of the reporter protein virus and an 
initial investigation of infection and expression conditions in small-scale experiments.  
Six-well plate HeLa cultures were used to study multiplicity of infection (MOI), 
volume during infection, and serum concentration during infection for their effect on 
EGFP expression level.  Maximum expression was achieved at an MOI of 1.0 with a 
0.5 ml infection volume in serum-free medium.  Additionally, twelve commercial 
microcarriers were evaluated for attachment and growth characteristics with HeLa 
cells.  Cytodex® 3 were found to be the most appropriate and were used to support 
growth of HeLa cells in spinner flask culture which, after infection with the reporter 
virus, produced 2.2 µg EGFP/106 cells at infection. 
Chapter 3 delved deeper into the infection and expression conditions through 
investigation of other parameters and infection of microcarrier based culture in 




addition relative to infection were evaluated in 6-well plate HeLa cultures.  One hour 
infection with 1.0 mM IPTG added at the time of infection provided a robust process.  
Evaluation of the best concentration of Cytodex® 3 microcarriers for growth of HeLa 
was performed and found 5 g/l to provide sufficient surface area for growth. MOI was 
reevaluated in the dynamic microcarrier culture environment which indicated a need 
for an increased number of virus particles per cell to 5.0, higher than that determined 
in Chapter 2 for plate culture.  Dissolved oxygen level and temperature during the 
protein production phase were evaluated for their effect on EGFP expression in 
microcarrier spinner flask culture.  Increasing dissolved oxygen to 50%, and 
decreasing temperature to 31°C, showed an increase in production over the course of 
the production phase.  The level of production achieved with this system reached ~17 
µg EGFP/106 infected cells.     
Chapter 4 expanded the process into perfused bioreactor culture and examined 
the effects of scaling up this viral process.  Perfusion growth of HeLa cells on 
microcarriers was studied with an alternating tangential flow device (ATF) which 
increased the length of the exponential phase and the maximum cell density, to 
4.4×106 cell/ml, compared to batch culture.  Concerns about seed train expansion 
were addressed by demonstrating that an in-flask trypsinization procedure could be 
used to provide the cells for seeding.  Dissolved oxygen and temperature were 
revisited in the large-scale environment because these parameters could be better 
understood in a system which isolates and separately controls these parameters.  A 
process where the DO and temperature were adjusted after infection to 50% and 




The defined process was then used to produce gp120, an HIV-1 envelope coat protein 
with complex post-translational modifications.  The purified protein was digested for 
glycosylation analysis, showing a significant amount of N-linked glycans and 
biological activity was determined by a fusion-inhibition assay resulting in an ID50 of 
3.1 µg/ml.   
Chapter 5 describes an investigation of the HeLa S3 suspension adapted cell 
line for production of recombinant proteins with vaccinia virus.  Cell suspension 
processes are more common and easier to implement in most bioprocess laboratories.  
A hollow fiber device was used for perfusion feeding of the bioreactor culture, in 
much the same way as the ATF was used for microcarrier culture.  Two process 
parameters were reevaluated in suspension culture in spinner flasks to determine if 
their effect varied from the microcarrier based system.  These were MOI and 
temperature.  Single cell suspension culture was thought to have different infection 
kinetics than microcarrier based culture.  The growth rate of HeLa S3 was somewhat 
higher than anchorage dependent HeLa cells, potentially altering the balance of 
reduced cytopathic effect from lowered temperature with lowered overall processing. 
An MOI of 1.0 lead to the highest level of intracellular expression of EGFP while 
reducing the temperature to 34°C during the protein production phase also increased 
production of the protein two-fold over the 37°C culture.  Scaling up the process to 
bioreactor culture with hollow fiber perfusion, lead to an overall production level of 
10.44 µg EGFP/106 infected cells, or 27 mg EGFP/l.  
The HeLa cell line is potentially inappropriate for regulatory approvable 




Chapter 6 evaluated the production of both EGFP and gp120 protein, produced in the 
cytoplasm and secreted into the medium, respectively, with five mammalian cell lines 
(HeLa, BS-C-1, Vero, MRC-5, and 293).  HeLa cells produced the most EGFP at 
17.2 µg/well with BS-C-1 and 293 following.  BS-C-1 produced the most gp120 at 
28.2 µg/ml with 293 and Vero following.  MRC-5 had a very high productivity on a 
per cell basis, but low cell density and slow growth rate made the overall production 
low.  Significant amounts of N-linked glycosylation modifications were found on the 
gp120 protein produced, based on PNGase digestion.   These results and 
consideration of other processing factors lead to a recommendation for further 
production process optimization in a serum-free suspension system using 293 cells. 
The work reported here demonstrates the capacity for the VOTE vaccinia 
virus expression system in production of recombinant proteins.  Various infection and 
expression related parameters were studied to continually increase production levels 
with this virus.  Additionally, some concerns raised by other researchers during 
presentations of this work about transfer of the process and suitability of 
manufacturing were addressed in Chapters 5 and 6.  Overall, we were able to achieve 
production of both intracellular and complex secreted proteins by this method and 
showed the appropriate processing and activity of the gp120 produced.   
7.2  Future Directions 
7.2.1  Scale-up of Microcarrier and Suspension Processes 
Future research could be aimed at further increasing the size of bioreactor 




should be able to increase in size through the use of larger bioreactor vessels.  The 
perfusion methods should also be scaleable with larger ATF or hollow fiber systems.  
Particular care will need to be taken during the infection process to ensure that 
controllable process parameters are not affected by the reduction in volume, as this 
will depend on the location of the various probes in the bioreactor and their ability to 
take accurate measurements during these medium manipulations.  These changes may 
also affect the process because they may take longer to perform at large-scale, and 
this will need to be taken into consideration when planning the infection and feeding 
timing.   
7.2.2  293 Serum-Free Suspension Growth and Vaccinia Virus Infection 
Some investigation of the growth of 293 cells in a serum-free suspension 
environment with a commercially available medium has already been performed in 
our lab, reaching 1.1×107 viable cell/ml.  This work could be utilized and infection 
conditions reevaluated with this cell line in serum-free suspension culture.  It may be 
necessary to either use DMEM without serum as the infection medium or contact the 
supplier of the serum-free medium to remove any serum like components and 
Pluronic F-68 from the medium for the infection phase, as these may prove to 
interfere with infection in the same manner as serum.  Bioreactor growth should be 
similar to other suspension processes such as the HeLa S3 and the results obtained 





7.2.3  CHO Cell Vaccinia Infection 
One industrially significant cell line that is an exception to the wide host range 
of wild-type vaccinia virus is the Chinese Hamster Ovary (CHO) cell line, commonly 
used for manufacturing processes.  Some work has been done by other researchers to 
overcome this host range restriction of vaccinia.  This was accomplished by inserting 
the cowpox hr (host range) gene into a recombinant vaccinia virus and resulted in 
permissive infection and production of recombinant chloramphenicol 
acetyltransferase (RamseyEwing and Moss 1996).  This vaccinia expression system 
was not inducible although it was controlled by the T7 promoter through which the 
T7 polymerase was produced via a vaccinia promoter.  Construction of a recombinant 
vaccinia with the VOTE, inducible, expression system containing a multiple cloning 
site would bring this virus construct in line with that used for the work described here.  
An investigation and optimization of a vaccinia based production process with the 
CHO cell line infected with this VOTE-CHO construct could prove more useful than 
other cell lines because of the broad knowledge available for CHO based processes.    
7.2.4  Manipulation of the Vaccinia Genome 
A newly emerging area of study with vaccinia virus is looking into the change 
of regulation of genes upon vaccinia virus infection (Guerra et al. 2003).  By utilizing 
the results obtained from these types of studies, researchers may be able to remove 
non-essential genes, thereby increasing the capacity for larger inserts.  There is also 
the potential to find genes which can be controlled to reduce the infectivity or 
cytophathic effects of the virus, leading to safer viral vectors that are permissive to 




possibility would be to genetically engineer the promoters controlling the genes 
regulating cytopathic effect or infection, thereby allowing inducible control of these 
processes.  This could result in a process where infection is only allowed during the 
prescribed period to allow generation of viral stocks or for the initial infection of a 
protein production process.  Through control of the cytopathic effects, which may be 
linked to infectivity, we could allow infection early in the culture, and then turn off 
the genes causing death in the cells while still allowing the viral and cellular 
machinery the opportunity to produce and process more protein.  This concept would 
be similar to using baculovirus to infect mammalian cell culture where the virus will 
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